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Abstract
Histopathological analysis of tumor is currently the main tool used to guide cancer
management. Gene expression profiling may provide additional valuable information for
both classification and prognostication of individual tumors. A number of gene expression
profiling assays have been developed recently to inform therapy decisions in women with
early stage breast cancer and help identify the primary tumor site in patients with metastatic
cancer of unknown primary. The impact of these assays on health and economic outcomes, if
introduced into general practice, has not been determined. I aimed to conduct an economic
evaluation of regulatory-approved gene expression profiling assays for breast cancer and
cancer of unknown primary for the purpose of determining whether these technologies
represent value for money from the perspective of the Canadian health care system. I
developed decision-analytic models to project the lifetime clinical and economic
consequences of early stage breast cancer and metastatic cancer of unknown primary. I used
Manitoba Cancer Registry and Manitoba administrative health databases to model current
“real-world” Canadian clinical practices. I applied available data about gene expression
profiling assays from secondary sources on these models to predict the impact of these assays
on current clinical and economic outcomes. In the base case, gene expression profiling assays
in early stage breast cancer and cancer of unknown primary resulted in incremental cost
effectiveness ratios of less than $100,000 per quality-adjusted life-year gained. These results
were most sensitive to the uncertainty associated with the accuracy of the assay, patientphysician response to gene expression profiling information and patient survival. The
potential application of these gene expression profiling assays in clinical oncology appears to
be cost-effective in the Canadian healthcare system. Field evaluation of these assays to
establish their impact on cancer management and patient survival may have a large societal
impact and should be initiated in Canada to ensure their clinical utility and cost-effectiveness.
The use of Canadian provincial administrative population data in decision modeling is useful
to quantify uncertainty about gene expression profiling assays and guide the use of novel
funding models such as conditional funding alongside a field evaluation.
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Chapter 1

1

Introduction

1.1 Gene expression profiling
Current goals in cancer research include the discovery of new cellular targets to exploit
for new targeted treatments, new biomarkers for early cancer detection, and providing a
better classification of cancers for prognostication and treatment decision [1]. Toward
this end, significant research efforts have been made to understand the molecular basis of
carcinogenesis and the biologic behavior of human cancers [1]. Due to the complexity of
the molecular alterations in tumor cells, progress has been slow. Carcinogenesis is a
multistep process in which cells accumulate altered expression of numerous genes as they
progress to a more malignant phenotype [2]. Confounding this complexity, many of the
so-called oncogenes and tumor suppressor genes are signaling molecules, which control
the expression of a subset of downstream genes [2].
Cells respond to environmental signals by modulating the expression of genes contained
within the nucleus. When genes are activated, they are transcribed to generate messenger
RNA (mRNA), which is transported from the nucleus to the cytoplasm and translated into
protein by the ribosomes.
Approximately 3 to 5 percent of genes are active in a particular cell, even though all cells
have the same information contained in their DNA. Most of the genome is selectively
repressed, a property that is managed by the regulation of gene expression, mostly in
transcription (i.e. the production of messenger RNA from the DNA). Changes in gene
expression in response to a cellular perturbation take place that result in the expression of
hundreds of gene products and the suppression of others. This molecular heterogeneity is
thought to explain, at least in part, the variability in outcome and response to therapy that
characterizes tumors of different histology [1-2].
Even tumors of a specific histological type can be quite heterogeneous. In general,
histopathological analysis of tumor tissue is the main tool that guides clinical
management decisions and prognostic estimates [1-2]. However, tumor behavior cannot
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be adequately understood through the analysis of one or a small numbers of genes,
particularly for the common solid tumors.
The analysis of multiple expressed genes or proteins provides more valuable information
for both classification and prognostication of individual tumors [1-2]. The development
of microarray methodology, which permits the expression of thousands of genes to be
tested simultaneously, represents a powerful technique to read the "molecular signature"
of an individual patient's tumor [3]. This process is called gene expression profiling.
Analyzing gene expression patterns among individual patients with the similar disease
may disclose molecular differences. Such classification may allow better treatment
selection and prognostication [2, 4].
While these discoveries increase our understanding of molecular pathogenesis, they can
also suggest novel therapeutic targets, provide information about drug resistance
pathways, and refine diagnostic and prognostic classifications [4]. For instance, a major
problem in clinical oncology is the heterogeneous response of histologically similar
tumors to treatments such as cytotoxic chemotherapy [5]. With the exception of estrogen
or progesterone receptor, and human epidermal growth factor receptor 2 (HER-2)
expression in breast cancer (for hormonal therapy and trastuzumab, respectively) [6],
epidermal growth factor receptor (EGFR) kinase domain mutations and genomic
amplification in lung cancer (in EGFR targeted inhibitors gefitinib or erlotinib) [7], and
K-ras mutations in colon cancer (lack of response to EGFR-targeted antagonists) [8],
there are no other single molecules that are clinically valuable predictors of response
validated for any form of anticancer therapy.
Growing data suggest that prediction of response to chemotherapy or biologically
targeted agents may be possible by analyzing gene expression profiles [9]. With rapid
advances in the DNA microarray technologies and more sophisticated studies, microarray
analysis has begun to make ways into clinical trials and practices in oncology [10-12].
Particularly, two major areas of investigation are the use of gene expression profiling
assays to guide cancer therapy and cancer diagnosis.
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1.1.1

Gene expression profiling to guide cancer therapy

A major area of investigation is the use of such molecular profiling to predict response to
therapy [13-17]. Gene expression profiling analysis by DNA microarray is now available
in patients with breast cancer to quantify the likelihood of a breast cancer recurrence in
women with newly diagnosed, hormone receptor-positive early stage breast cancer [11,
18-20]. Furthermore, there is growing evidence that gene expression profiling analyses
can help predict which patients are most likely to benefit from chemotherapy [11, 18-20].
To date, several gene expression-based tests have demonstrated the potential value of this
approach. The 21-gene recurrence score (RS) assay (Oncotype DX, Genomic Health Inc.,
Redwood City, CA) [11, 18] and MammaPrint (Agendia, Irvine, CA and Amsterdam,
The Netherlands) [21-22] are commercially available gene expression profiling assays
that are used to inform treatment decisions based on tumour biology. However, the RSassay is becoming widely accepted as having clinical validity and utility for this purpose
[23].
The RS-assay is a RT-qPCR based signature that measures the expression of 21 genes (16
cancer related and 5 reference genes). RNA is obtained from formalin-fixed paraffinembedded (FFPE) tissue samples. The RS-assay is recommended for patients with
hormone receptor positive and human epidermal growth factor receptor 2 (HER-2) not
over expressed axillary lymph node negative early stage breast cancer. The test requires
assessment of estrogen receptor and HER-2 status by an alternative method [18]. The RSassay became the most widely used clinical gene expression assay in the United States.
The genes in the assay were selected from 250 candidates that were tested for association
with survival in a cohort of 447 tumor samples, from the tamoxifen treated and node
negative cases of the National Surgical Adjuvant and Breast Project (NSABP) B-20
clinical trial [24]. The RS-assay was validated in a large cohort of estrogen receptor
positive node negative breast cancer patients treated with tamoxifen, enrolled in the
NSABP B-14 study [18]. In this study, the rates of distant recurrence at 10 years were
6.8%, 14.3%, and 30.5% for the low-risk, intermediate, and high-risk groups,
respectively [18]. The RS is a continuous variable, ranging from 0 to 100, and constitutes
a measure of the risk of relapse within 10 years. The score is an independent prognostic
factor for patients with hormone receptor positive breast cancer treated with adjuvant
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tamoxifen. Patients can be classified into three categories on the basis of RS. Low risk
(RS<18), intermediate (RS 18-31), and high (RS>31), which equate with 10 year relapse
rates of 7%, 14%, and 30%, respectively. Women in the low risk group do not seem to
benefit from adjuvant chemotherapy as shown in the NSABP-B20 analysis that randomly
assigned patients to receive cyclophosphamide, methotrexate, 5-fluorouracil (CMF)
chemotherapy with concurrent tamoxifen or tamoxifen alone [11]. Only a small subset of
tissues was available for analysis (651 samples from 2363 randomized patients). The
analysis showed that their distant metastasis free survival is higher than 90% regardless
whether or not they received CMF chemotherapy. In contrast, women in the high-risk
group derived benefit from adjuvant CMF chemotherapy [11]. The question remains
unanswered for women who fall into the intermediate-risk group. The current ongoing
Trial Assigning IndividuaLized Options for Treatment (TAILORx) [25] and Southwest
Oncology Group (SWOG) S-1007 [26]) seeks to answer this question by randomly
assigning patients with intermediate RS to adjuvant chemotherapy followed by antiestrogen treatment or anti estrogen treatment alone.
MammaPrint (Agendia, Irvine, CA and Amsterdam, The Netherlands) is a microarraybased gene-expression profiling assay of RNA [21-22]. The test is comprised of 70 genes
identified from an initially unselected set of all >25,000 genes within the human genome
which were obtained from fresh frozen samples of tumor tissue [21]. New studies have
demonstrated that the test could be done by RT-qPCR, both in fresh frozen and formalinfixed paraffin embedded tissue, with equivalent performance [27]. The genes are
associated with all hallmarks of cancer including proliferation, invasion, and
angiogenesis. The genes were obtained from tissue of 78 patients with lymph node
negative breast cancers, most of which were hormone receptor positive tumors and did
not receive adjuvant systemic therapy [21]. This signature has been validated on
numerous cohorts of node negative patients, and has demonstrated to provide
independent prognostic information beyond standard clinicopathological variables such
as age, histology, tumour grade and pathological stage [21, 28-29]. The test can be used
in estrogen negative breast tumors.
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Mammaprint is the first and so far only Food and Drug Administration (FDA)-approved
gene-expression assay to be used as prognostic test for women with node-negative breast
cancers [30]. The test yields two prognostic groups: low-risk and high-risk. This
signature is predictive of both distant disease-free survival and overall survival when
adjusted for lymph node status. Patients in the low-risk group have a distant metastasis
free survival of over 90% without the addition of systemic chemotherapy [21].
Overall published evidence supports MammaPrint as a better predictor of the risk of
distant recurrence than traditionally used tumour characteristics or algorithms, but its
performance in therapeutically homogenous populations is not yet known with precision,
and it is unclear for how many women the lowest predicted risks are low enough to forgo
chemotherapy [23]. No evidence is available to permit conclusions regarding the clinical
utility of MammaPrint to select women who will benefit from chemotherapy [23].
The key components of the RS-assay used for clinical care are the RS and corresponding
RS category [23]. These data are based on the clinical trials from which the RS-assay
method was derived and validated. Although the MammaPrint and other assays under
development [30] do provide risk categories, the available evidence does not show that
the results of these assays have equivalent clinical utility to the RS-assay [23]. In
particular, the RS can be interpreted in the context of the NSABP B14 and B20 clinical
trials [11, 18] data to estimate the probability of recurrence without treatment and of
chemotherapy benefit, respectively. The equivalent data cannot be extracted from other
assays. In addition, direct prospective comparisons between the RS-assay and alternatives
are lacking.
Gene expression profiling assays are also being investigated as a tool to predict the
likelihood of disease recurrence and guide adjuvant treatment in individuals with colon
cancer [31]. Currently, five tests have been launched and shown to have prognostic value
in independent patient series, although the designs and sample numbers of the validation
analyses have varied [32-33]. The 12-gene assay (Oncotype Dx® Colon Cancer,
Genomic Health Inc., Redwood City, CA) [34] is the only test that is available outside of
research settings, although it has not yet been recommended for clinical use.
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This assay is based on the use of quantitative reverse transcriptase-PCR (RT-PCR) that
measures the expression level of a subset of 12 genes, which includes seven genes for
relapse-free survival prognosis and five reference genes that yielded a prognostic
recurrence score (RS) [35], ranging between 0 and 100. Patients are classified into three
categories based on their RS: low risk (RS < 30), intermediate risk (RS 30–40), or high
risk (RS > 40). Moreover, this test reveals another parameter termed, treatment score that
may point on the degree of benefit from adjuvant chemotherapy [35].
The test was based on four adjuvant studies that were conducted by the “National
Surgical Adjuvant Breast and Bowel Project” (NSABP) and the “Cleveland Clinic
Foundation” [36]. A validation study using archival fixed paraffin-embedded tumor
tissue specimens from 1,436 patients with stage II colon cancer who were randomly
assigned between adjuvant chemotherapy and surgery alone (QUASAR) confirmed the
clinical utility of the RS score [35]. It is essential to emphasize that the test is mostly
accurate in early stages of colorectal cancer, when a 5-FU-based chemotherapy is being
considered. High-risk patients, as well as, patients that are candidates for other
chemotherapeutic treatments, require further investigation [37].

1.1.2

Gene expression profiling to guide cancer diagnosis

Another major area of investigation is the use of gene expression profiling for diagnosis
in patients with cancer [38-40]. Specific gene expression profiles based on the tissue of
origin have been identified for many tumor types. Because histogenetic information is
maintained during metastatic process, gene expression pattern of a metastasis may reflect
the histogenetic make-up of the primary tumour [41]. It is becoming possible to use gene
expression-based analysis to assist in identification of the primary site [41]. Thus, several
multigene assays have been developed for the purpose of identifying the tissue of origin
in patients with cancer of unknown primary.
To date, several gene expression-based tests have demonstrated the potential value of this
approach. Although these tests use different microarray platforms, classification
algorthims, and sample selection criteria, the overall accuracy of the confirmation of the
primary site of origin was 75% to 89% [12, 39, 42-53]. Most of the commercially
available tests have shown promising results in the internal validations (i.e., using same
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specimens used for a test development) and have been translated to RT-PCR or robust
microarray platforms [48]. However, other well identified requirements should be taken
into account when translating and validating these tests for clinical use. According to
guidelines for translation of genomic classifiers and for validation of clinical molecular
tests [54-56], demonstration of reproducibility and adequate external validation analysis
(using specimens other than those used for a test development) are required. External
validation of a test for tumour classification needs to have a statistically valid sample
size, inclusion of enough specimens for each tumour class to be identified, and inclusion
of indeterminate results in overall performance [54-55]. According to these guidelines we
will review in the following two paragraphs the publicly available evidence for each
commercially available test.
The Tissue of Origin (TOO) test is commercially available by Response Genetics (Los
Angeles, CA) and clinically offered in the United States. The test is the only assay that
has been reviewed and cleared by the Food and Drug Administration [57]. The TOO test
compares the RNA profile (a 2000-gene profile) of a tumour FFPE specimen to
established RNA profiles of 15 known tissues, representing 90% of all solid tumours. The
test measures the degree of similarity between the expression patterns of the tumour and
those of a panel of 15 different tissue types [58]. The tumour tissue types represented are
bladder, breast, colorectal, gastric, hepatocellular, kidney, non-small cell lung, ovarian,
pancreatic, prostate, thyroid carcinomas, melanoma, testicular germ cell tumour, nonHodgkin’s lymphoma, and sarcoma. The test result is presented as 15 separate similarity
score (SS) (which are interpreted as probabilities), one for each tissue type on the panel.
The highest SS indicates the most likely tissue of origin. Any tissue type on the panel
with an SS of ≤5% is ruled out as a possible origin of tumour tissue with >99%
confidence.
The test requires an FFPE biopsy block (including block of solid tissue, cell buttons from
fine needle aspirates, cell buttons from malignant effusions, or core needle biopsies)
containing at least 1mm2 of tumour tissue [58]. The test can also be performed using a
minimum of 3 unstained slides of at least 5µm-thickness from any of the biopsies
mentioned. A minimum of 30 ng FFPE-derived RNA is sufficient to perform the test
[58].
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The test was developed on a gene expression microarray (PathChip) platform that showed
adequate reproducibility in an interlaboratory comparison study. Thus, the platform
appears suitable for clinical application. The test was validated on independent 462 FFPE
specimens derived from metastatic or poorly differentiated tumor specimens of known
primary cancers and showed 89.3% accuracy in identifying tumour’s primary site [59].
The large number of specimens included in the external validation allowed for class
representation of at least 25 specimens per tissue type, and inclusion of indeterminate
results. Thus, the test appears to fulfill the criteria for successful translation outlined
above [54-55] as was also judged by the FDA [60].
The first gene expression-based test for determination of the primary tumour site to be
clinically available was the Cancer-TYPE ID test, developed by BioTheranostics as a
laboratory-developed test (LDT). The test is an RT-PCR 92-gene assay that is reported to
classify 39 different tumour types and 64 subtypes [11]. The test was evaluated with
independent 119 FFPE tumour specimens and showed an overall accuracy of 86% [11].
However, the reproducibility of the test has not yet been adequately shown [48]. Another
test available in the United States is the miRview mets test from Rosetta Genomics
(Philadelphia, Pennsylvania), which is also offered as an LDT. The test is an RT-PCR 48microRNA (miRNA) assay that is reported to classify 25 different tumour types [49]. The
test was evaluated in 80 independent tumour specimens (12 frozen /68 FFPE) but the
study authors did report the overall accuracy of the confirmation of the primary site [49].
It is not possible to determine if the assay was successfully translated to the RT-PCR
platform due to lack of published data, including data regarding reproducibility of the test
[48]. The CUPrint test is a 1900-gene GEM test that was developed by Agendia BV
(Amesterdam, The Netherlands) and is only available outside the United states in
Agendia’s CLIA-certified laboratory. This test is reported to classify 11 different tissue
types. Agendia did not translate the test to an RT-PCR platform but used a robust
customized microarray instead [61]. In terms of external validation, the test was
evaluated on an independent sample set of 84 primary and metastatic tumours
representing 9 tumour types and showed an overall accuracy of 83% [45]. The CUP
assay, developed by Veridex (LA Jolla, California), evaluates the expression of 10 tissuetype specific gene markers by using quantitative RT-PCR and is designed to detect
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tumours from 6 specific sites: lung, breast, colon, ovary, pancreas, and prostate [12, 51].
The test is not commercially available. The small number of genes evaluated has limited
the number of tissues that can be distinguished by this assay. The test was evaluated with
independent 37 FFPE tumour specimens and showed an overall accuracy of 75.6%. 50%
of tumours outside of the 6 targeted tissue types were incorrectly assigned to 1 of these
tissue types [48].
Overall, peer-reviewed evidence has shown that the quality of the external validation
studies for these tests is insufficient [48]. These validation studies have been restricted to
a small number of specimens and do not have adequate representation for all tumour
tissue types being evaluated. For instance, a claim has been made of 100% sensitivity for
a specific tissue type, with only 1 or 2 specimens for the tissue type in the validation
sample [48]. Furthermore, data regarding specificity (i.e., how often the negative result is
correct) are not publically available for these tests.
Although different assays have been used, these panels appear to be accurate in 80 to 90
percent of cases of patients using tissue from metastases in patients with known primary
tumors [39]. Experience in patients with adenocarcinoma of unknown primary is more
limited. The accuracy of diagnosis by molecular profiling has recently been studied
retrospectively in a group of 20 patients who initially had CUP but subsequently had a
primary site identified clinically [38]. The primary sites identified by the molecular
profiling assay (from the original metastatic tumor biopsy) matched the subsequent
clinical diagnosis in 15 of 20 patients, further supporting the value of this diagnostic
method [38].
Gene expression profiling is likely to be a valuable addition to the diagnosis and
management of patients with CUP. However, definitive demonstration of its value in
improving treatment outcome for these patients is not available. Ongoing clinical trials
are evaluating the efficacy of treatment directed by RT-PCR assay results, as well as
comparing the utility of the several available assays.
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1.1.3

Obstacles to incorporating gene expression profiling
in clinical practice

Using these gene expression profiling tests in clinical oncology poses several questions:
How convincing is the data? Most companies support their claims about these tests,
which cost from about $3,000 to more than $5,000 per patient, with data from
retrospective analyses rather than prospective trials. Large ongoing trials for some of
these tests may increase practitioners’ comfort with them, but final data are years away
and a funding decision may need to be made prior to having full efficacy or effectiveness
data of these gene expression applications. Thus, reimbursement policies and clinical
validation are still the main obstacles for personalized medicine in oncology. The impact
of these innovations on health and economic outcomes, if introduced into general
practice, has not yet been determined. As these tests are expensive there are important
tradeoffs to consider in deciding whether to adopt these tests in a resource constrained
system such as the Canadian health care system.

1.2 Cost Effectiveness Analysis
Cost effectiveness analysis (CEA) is a commonly used technique to assess the “value-formoney” of new medical technologies such as drugs, devices, policies, medical
procedures. For a given level of resources available, society or decision maker wishes to
maximize the total aggregate health benefit conferred [62]. International decision making
bodies such as the National Institutes for Health and Clinical Excellence (NICE) in the
United Kingdom (UK) [63] and the Pharmaceutical Benefits Advisory Committee
(PBAC) in Australia [64] have formally incorporated CEA into their processes for
reviewing new medical technologies and inform health technology adoption decisions
[65]. Similarly, the Common Drug Review (CDR) in Canada [66] considers CEA when
considering reimbursement of new pharmaceuticals.
CEA involves a formal comparison of the incremental costs and incremental benefits
associated with incorporating a new medical technology into an existing standard of care.
Costs are expressed in currency units, and benefits are expressed in common units such
as life expectancy (i.e., “life years gained”). The frequent use of “life year gained” which
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has been used as the chief outcome variable in CEA is considerably restrictive. CEA
produces a more robust and meaningful outcome measure by combining the quality and
quantity of the outcomes [67]. Therefore, Quality Adjusted Life Year (QALY) has
become a common metric in CEA. QALYs are life years that have been adjusted by a
value between 0 and 1 to reflect difference in quality of life for difference health
conditions. Results of a CEA are usually presented in the form of a ratio called the
incremental cost-effectiveness ratio (ICER) where the ICER associated with
incorporating a new medical technology is given as by:
௦௧
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Because CEA involves marginal cost and benefits, the choice of which current standard
of care or technology to compare can drive the calculation and the conclusion of a CEA
(i.e., an appropriate definition for “Current” in the ICER equation). Therefore, CEA is
very sensitive to the choice of strategies being compared. The new medical technology is
then considered “cost-effective” based on a value judgment (what cost is considered a
good price for an additional outcome) [68]. Several heuristics are commonly used to
assist in making this value judgment including plotting the incremental cost and
effectiveness in a cost-effectiveness plane [69] comparisons with other technologies in a
league table [70] and comparisons with pre-specified thresholds (e.g., £30,000 / QALY
gained in UK [71] or $100,000 / QALY gained in Canada [62, 72]).

1.2.1

Models and parameterization in CEA

There are two common approaches for parameterization in CEA of a new medical
intervention. In the first, data for CEA are estimated directly from a single clinical trial
(i.e., use of resources are collected concurrently with the clinical trial). In this case, the
economic data can be viewed as experimental and are typically analyzed in the same way
as the clinical data. In the second approach, decision analytic models (e.g., decision trees,
Markov models, and Monte Carlo simulation models [73]) are used and data from a
number of sources are synthesized [74]. The data for this type of CEA could be a mix of
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experimental (e.g., efficacy data from randomized clinical trials), observational (e.g.,
resource-use data extracted from patient chart review or a claims database), routine
statistics (e.g., data delineating the unit costs or prices of resources), local surveys (e.g.,
data showing how therapies effect patients’ quality of life), or expert opinions (e.g., data
describing the physical quantities of resources consumed by the strategies being
compared). Even randomized clinical trial-based CEAs often use some data obtained
from outside the clinical trial, such as the prices (or unit costs) of health care resources.
It has been argued that CEAs using experimental data are the most internally valid and
meet the biostatistical and epidemiological rules, in that the differences between medical
interventions being compared are unlikely to be biased [74]. However, several factors
may still limit the internal and external validity of experimental data and consequently
the results from CEAs using these data.
Clinical trials usually include only a small fraction of the targeted general population.
Thus, the experience of participants in these trials may not reflect the experience of the
targeted general population [75-76]. Studies have suggested that the observed effects in
these trials may not necessary reflect the effects of the treatments or technologies under
investigation [77-78]. Clinical trials are usually of limited duration of follow up relative
to the possible duration of impact of the alternatives. In addition, many CEA guidelines
call for use of a “lifetime” horizon. This set of factors necessitates extrapolation of
clinical trial data when used in cost-effectiveness analyses using models (e.g. Markov
chain simulation) to assess the long-term impact of the alternative treatment options on
cost and effectiveness [79]. Moreover, there are circumstances where randomization may
not be possible such as studies aiming to investigate the impact of adherence to drug
treatmenton clinical outcomes in real-world settings.
A modeling-based CEA offers the potential for generalization and for transferring the
results to other settings. However, clinical (both experimental or observational) and
economic data reported in the literature and commonly used in these analyses, may not be
entirely relevant to the population in the studied geographic region and setting in which
alternatives are likely to be applied in the real world [80]. Ultimately, data used in CEAs
should be extracted from settings that accommodate socioeconomic variability and are
likely to reflect regular clinical and economic experience of the relevant patient
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population under investigation in the studied geographic region with long follow up
periods [81].
Disease registries and administrative health databases can be valuable clinical and
economic data sources for conducting CEAs [82]. These databases contain records of
events that have occurred under everyday conditions. The main advantage of using these
databases is that interventions or technologies studied in CEAs can be described under
actual “real world” conditions that are relevant to the studied geographic region [81].The
alternative is to use literature from clinical trials or observational studies data. These
databases are often population based (i.e., minimizing selection bias), have high rates of
disease ascertainment (i.e., disease prevalence and incidence), and include a large-enough
population over a long-enough time period to evaluate effectiveness and costs among
different age- or race-specific population subgroups [83-84].

1.2.2

Administrative health data in Canada

1.2.2.1 Provincial administrative health databases
In Canada, provincial governments are generally responsible for the funding of inpatient
and outpatient hospital services and physician services (Table 1) as per the Canada
Health Act [85]. In addition, some provincial governments fund other services such as
non-physician professional services (e.g. chiropractic, optometry), prescription drugs
(i.e., with eligibility criteria), vaccines, home care, and long-term care. Each provincial
government maintains records of utilization for most of these services. The maintenance
of these records forms the provincial administrative health databases (Table 1).
In addition, each province maintains a population registry where each resident is assigned
a unique identifier (scrambled ID) which is often in the form of a health plan number
(health insurance number). For example in Ontario, the unique identifier is the Ontario
Health Insurance Plan (OHIP) number. This unique identifier is used to record each
service in the provincial databases. Via the unique identifier, an analyst can link available
records for drugs, physician visits, hospital discharges, and some outpatient visits to form
a unique patient record. This record could include all information for all the patient’s
services.
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Linkage is useful because it allows analysts to identify patients with specific
characteristics in one database, and then gather additional information about those
patients using other databases. For example, patients who received hospital-based and
community-based emergency and ambulatory care can be identified in Ontario using the
National Ambulatory Care Reporting System (NACRS) and then get their OHIP billing
claims before and after.

1.2.2.2 National administrative health databases
The Canadian Institute for Health Information (CIHI) facilitates the development and
maintenance of an integrated health information system at a national level. In particular,
CIHI, in co-operation with the provincial governments, develops data standards for some
databases such as inpatient care, ambulatory care, and pharmaceuticals. The provinces
maintain their own data systems which may be more complete than the requirements
specified by CIHI, and submit their patient or client data on hospital care and physician
care to CIHI using the CIHI standards on a quarterly or annual basis.
The CIHI databases are most useful when one wants to obtain data on overall counts of
services and on overall costs without identifying how many people have received these
services. CIHI does have unique identifiers, but they do not have population registry data.
Unique identification is not always accessible to researchers outside CIHI, whereas some
provinces (Manitoba, Quebec, and Ontario in particular) have a long history of successful
research collaboration with academics.

1.2.2.3 Disease registries
Disease registries are surveillance systems which maintain records of patterns of medical
history, diagnostics or treatment in patients with a specific disease and follow outcomes
or survival patterns over time. In Canada, patients are often identified using the same
unique identifiers used in the population registry. This allows researchers to link disease
registries with administrative databases to build detailed longitudinal records of their
treatments and health care utilization.
There are several disease registries in Canada. However, the most well established are the
cancer registries. These cover the entire population, with all provincial and territorial
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registries reporting to the Canadian Cancer Registry (CCR). The overall coverage for
cancer incidence data is estimated to be at least 95% [86]. Although these registries differ
somewhat in their approaches and methods, their procedures for registration are fairly
consistent, and comparable surveillance data from each province are reported up to the
CCR level.
There are other disease registries in Canada that have also instituted surveillance
operations and built databases of patients with specific diseases. The Canadian Organ
Replacement Registry, managed by CIHI, organizes organ replacement and end stage
renal failure records for all 84 organ replacement centers across the country. Starting in
May 2001, the Canadian Joint Replacement Registry (CJRR), managed by CIHI and
orthopedic surgeons, collects information on hip and knee joint replacements performed
in Canada. The CJRR follows joint replacement patients over time to monitor their
revision rates and outcomes. The Canadian Trauma Registry has accommodated the
records of all Ontario accidental injuries and is currently expanding to cover all Canada.
In addition, the Institute for Clinical Evaluative Sciences (ICES) has recently received
Canadian Institute for Health Research (CIHR) funding to develop a Canadian stroke
registry.

1.2.3

Use of administrative health data for descriptive
costing studies

In Canada, analysts can use the information in health administrative databases to describe
the health care utilization and direct costs that are associated with persons with specific
medical conditions or who use specific drugs or services. The utility of administrative
data for descriptive costing has been demonstrated in a number of analyses. For example,
Krahn et al. [87] used the Ontario Cancer Registry, Discharge Abstract Database, Claims
History Database of the OHIP, National Ambulatory Care Reporting System and other
administrative databases in Ontario to estimate the total healthcare costs and costs
attributable to prostate cancer across all stages of disease. Another analysis by Carriere et
al. [88] used the Canadian Institute for Health Information’s Inpatient Discharge Abstract
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Database for the province of Alberta and Alberta Health Insurance Plan Registry to
determine the cost per day for the treatment of community-acquired pneumonia.

1.2.3.1 Case definition
When using administrative data to estimate cost of health care utilization of disease (i.e.,
cost of illness) the analyst must first develop criteria to identify the patient population of
interest. For instance, Blanchard et al. [89] developed such criteria for identifying
diabetes cases using Manitoba administrative data. Blanchard et al. [89] defined a
diabetes case as a patient record with two or more diabetes diagnoses at different visits in
the physician billings data during a two-year period or one diagnosis in the hospital
inpatient data. Another analysis by Simpson et al. [90] used an expanded definition with
Saskatchewan administrative data to measure costs during a 10-year period for persons
who had no previous diabetes records. In that definition, the dispensing of insulin or an
oral antidiabetic drug was added to the list of possible indications. In case of a narrower
target patient population of interest (i.e., persons with diabetes who have nephropathy)
the analyst must develop a more detailed algorithm to define the disease. For example,
Bernstein [91] used Manitoba administrative data and developed a case definition for
inflammatory bowel disease (IBD). Bernstein [91] defined a case as IBD if the physician
billing records showed at least five physician visits that were coded as IBD during any
time span that was greater than two years. When cases with specific medical conditions
of interest are captured by disease registries, the analyst may use data captured by these
registries to identify those cases. For instance, a recent analysis by Oliveira et al. [92]
used the Ontario Cancer Registry to identify patients diagnosed with the 21 most
common cancer sites in Ontario. After identifying the patient population of interest, the
analyst can take an incidence approach or prevalence approach for costing of illness
using administrative data.

1.2.3.2 Incidence approach for costing of illness
The incidence approach allows analysts to track costs (i.e., longitudinal costing) from the
time when the disease is diagnosed until a desired end point (e.g., cure, disease
progression, or death). For a chronic disease, the tracking may require years of
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observation. For instance, Johnston et al. [93] measured the cost of hospital, physician,
and drug services for persons with diabetes, for 10 years from the time of incidence.
Analysts may find the incidence approach to be useful in determining cost of resource use
that is avoided because of cases that avoided. This approach would be useful in particular
to planners who want to determine the economic impact of a preventive measure.
Analysts may also find the incidence approach for costing to be useful in examining the
impact of disease severity at diagnosis on health care utilization and costs. For instance,
Mittman et al. [94] used the Ontario Cancer Registry to identify incident cases of
colorectal cancer and obtained information about colorectal cancer stage at diagnosis.
Mittman et al [94] linked those cases with the Home Care Administration database and
the Registered Persons Database to estimate the cost of home care services over the
patient observation time by stage of colorectal cancer at diagnosis. Importantly, the
incidence approach for costing has been useful in examining the impact of the phase of
care on health care utilization and costs.
In the phase-based costing approach to costing, the analyst divides the patient’s follow up
time to discrete phases. The time frame for each phase should be defined and a hierarchy
of time frames should be specified when necessary so that all phases stay mutually
exclusive. In 2013, Oliveira et al. [92] used a phase-based approach to examine the costs
of health care incurred before and after cancer diagnosis. Oliveira [92] used the Ontario
Cancer Registry and Ontario administrative data to identify incident cases of cancer.
Patient’s observation time was divided into two discrete periods: the pre-diagnosis phase
and initial care phase. The pre-diagnosis phase was defined as the 3 months before
diagnosis. The initial care phase included the date of diagnosis and the subsequent 12
months. Recently, Mittmann el al. [94] used a phase-based costing approach to costing
home care services for incident cases with colorectal cancer in Ontario. Mittman et al.
[94] divided the time horizon following diagnosis into three discrete care phases: initial,
continuing, and terminal. The initial care phase was defined as the first 6 months
following the diagnosis of colorectal cancer. The terminal care phase was defined as the 6
months before death and applied to patients who died during follow-up period. The
continuing care phase was defined as the time between the initial and terminal phases.
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The following hierarchy of time frames was used: terminal care> initial care> continuing
care, such that all phases were mutually exclusive.

1.2.3.3 Prevalence approach for costing of illness
The prevalence approach focuses on the costs of all cases with the disease during a fixed
period (e.g., a year). Using this approach, the analyst will include all cases with the
diagnosis, even if the incidence of the disease occurred in a prior year. Jacobs et al. [95]
used the prevalence approach to calculate the direct medical care costs of diabetes using
administrative databases from Manitoba. Jacobs et al. [95] studied the net (i.e.,
attributable costs) by subtracting the costs per person with diabetes from the per-person
costs of the non-diabetic population. Simpson et al. [90] used the same approach to
estimate direct medical care cost of diabetes using administrative databases from
Saskatchewan. However, Simpson et al. [90] used diagnostic codes to identify services
that were related to the diagnoses of diabetes.

1.2.4

Use of administrative health data in CEA

Despite the potential advantages from disease registries and administrative health data in
CEAs, the use of these data to conduct CEAs in Canada is relatively uncommon. In one
of the first economic evaluations using Canadian administrative data, Brown MG [96]
studied the cost-effectiveness of New Brunswick’s Extra-Mural Hospital (EMH) home
health care program using population-based administrative data on physician services
utilization to examine whether home care services act indirectly as substitutes for
physician services. Brown MG suggested that the introduction and expansion of New
Brunswick’s EMH home health care program have unanticipated substitution effects,
which reduce health system costs by reducing the rate of growth of per-capita utilization
of physician services.
In another analysis, Najafzadeh et al [97] studied the cost-effectiveness of herpes zoster
(HZ) vaccine versus status quo (no HZ vaccine) from the perspective of the Canadian
healthcare payer. They estimated health resource utilization using administrative data
retrieved from the British Colombia from 1994 to 2003. They reported an ICER of
41,709 per QALY gained for a cohort of elderly subjects aged ≥ 60 years and concluded
that HZ vaccination of adults, specially for individuals aged 60-70 years, seems to be a
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cost-effective intervention and might be considered by Canadian decision makers.
Recently, Sander et al [98] reported an economic evaluation of Ontario’s universal
influenza immunization program (UIIP) compared to a targeted influenza immunization
program (TIIP) using Ontario health administrative data. They estimated an ICER of
10,797 per QALY gained and concluded that the UIIP compared TIIP is an economically
attractive intervention.

1.2.5

Decision Analytic Models and Cost Effectiveness
Analysis in Oncology

Decision analytic models have been used extensively to evaluate health technologies
related to oncology. Examples include cost effectiveness analyses of preventive strategies
for women with BRCA1 or BRCA2 mutations [99]; HER testing and trastuzumab
treatment for breast cancer [100]; the cost effectiveness of various strategies for screening
for colorectal cancer [101-104]; the cost effectiveness of different treatment options for
prostate cancer [105-106]; and cost effectiveness analyses of specific drugs [107-110].
This represents a portion of work in the area. Searches of common medical databases for
terms related to cost effectiveness analysis and oncology yield thousands of results.
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Chapter 2

2

Objectives and research framework

I aimed to conduct an economic evaluation of potential application of major gene
expression profiling assays in breast cancer and cancer of unknown primary for the
purpose of determining whether these applications represent value for money from the
perspective of the Canadian health care system. The research proceeded with the
following steps:
•

Develop decision-analytic models. These models include decision trees with several
Markov models as the terminal nodes in the trees. Markov models are used to
simulate cancer progression correspondent with certain disease severity or different
types of cancer.

•

Fit models parameters using three main sources of information: Manitoba Cancer
Registry, Manitoba health administrative databases, and use of secondary sources and
the existing literature to estimate some additional models parameters of interest, such
as quality of life for various health states and sensitivity and specificity of molecular
profiling assays.

•

Set the models to perform cost effectiveness analyses of different molecular profiling
assays. The cost-effectiveness analyses are conducted according to recommendations
by the Canadian Agency for Drugs and Technologies in Health [111]. Results are
presented in the form of ICER which provides a measure of average cost per
additional unit of health benefit. Outcomes for health effects are measured in QALYs
(i.e., life-years weighted by utility estimates to produce QALYs). Cost outcomes are
measured as the mean cost per patient.

•

Conduct one-, two- and three-way deterministic sensitivity analyses on parameters of
interests to characterize uncertainty in the output measures and determine the
minimum conditions in terms of cost and accuracy for which these molecular
profiling assays would be cost effective. This helps to provide insights about the
potential economic attractiveness of assays that are still in various stages of
development and regulatory approval.
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•

Conduct probabilistic sensitivity analysis using Monte Carlo simulation to
understand the robustness of the results. Each iteration consists of a random draw
from an appropriate distribution for all model inputs to produce a distribution of
model outputs.

•

Conduct value-of-information analysis [112] as part of the sensitivity analysis to
determine the expected monetary value of perfect information about these molecular
profiling assays in the Canadian setting. In particular, baseline decision models are set
up to express molecular profiling assay related parameters (i.e., sensitivity and
specificity of the assay) as probability distributions (i.e., reflecting uncertainty of that
assay in the Canadian setting) on the basis of available validation analyses and the
entire model is set up as a probabilistic model. Using simulation techniques (i.e.,
making random draws of the probabilistic model), the level of uncertainty in the
model is assessed. Using a willingness to pay threshold [69], the opportunity cost
associated with the choice of a molecular profiling assay as the optimal strategy is
calculated and presented as a total of expected value of perfect information (EVPI)
about a given assay per patient. Using the size of patient population, the EVPI about a
gene expression profiling assay is calculated for the entire target population that could
potentially benefit from more research on the predictive value of that assay in the
Canadian setting. The EVPI provides decision makers with valuable information
about the use of novel funding models such as conditional funding alongside a field
evaluation [113].
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Chapter 3

3

Cost-effectiveness of a 21-gene recurrence score
assay versus Canadian clinical practice in women with
early-stage estrogen- or progesterone-receptorpositive, axillary lymph-node negative breast cancer

3.1 Abstract
A 21-gene recurrence score (RS) assay may inform adjuvant systematic treatment
decisions in women with early stage breast cancer. I sought to investigate the cost
effectiveness of using the RS-assay versus current clinical practice (CCP) in women with
early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative
breast cancer (ER+/ PR+ LN- ESBC)from the perspective of the Canadian public
healthcare system. I developed a Markov model to project the lifetime clinical and
economic consequences of ESBC. I evaluated adjuvant therapy separately in post- and
pre-menopausal women with ER+/ PR+ LN- ESBC. I assumed that the RS-assay would
reclassify pre- and post-menopausal women among risk levels (low, intermediate and
high) and guide adjuvant systematic treatment decisions. The model was parameterized
using 7 year follow up data from the Manitoba Cancer Registry, cost data from Manitoba
administrative databases, and secondary sources. Costs are presented in 2010 CAD.
Future costs and benefits were discounted at 5%.The RS-assay compared to CCP
generated cost-savings in pre-menopausal women and had an ICER of $60,000 per
QALY gained in post-menopausal women. The cost effectiveness was most sensitive to
the proportion of women classified as intermediate risk by the RS-assay who receive
adjuvant chemotherapy and the risk of relapse in the RS-assay model. The RS-assay is
likely to be cost effective in the Canadian healthcare system and should be considered for
adoption in women with ER+/ PR+ LN- ESBC. However, ongoing assessment and
validation of the assay in real-world clinical practice is warranted.
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3.2 Introduction
In 2011, an estimated 23,200 women in Canada will be diagnosed with breast cancer
[114]. Approximately half of them will be diagnosed with early-stage estrogen- or
progesterone-receptor-positive, axillary lymph-node negative breast cancer (ER+/ PR+
LN- ESBC) [115]. Standard care for these patients usually includes local therapy (surgery
with or without radiation) followed by adjuvant systematic therapy such as endocrine
therapy alone (tamoxifen or aromatase inhibitors) or chemotherapy followed by
endocrine therapy [116]. Canadian guidelines specify that a patient’s risk of recurrence
can be classified as low, intermediate or high and that adjuvant chemotherapy may be
added when the benefits of treatment outweigh toxicities of therapy [117]. However,
evaluating the risks and benefits of chemotherapy based on the Canadian guidelines is
difficult because the histopathologic measures that inform the guidelines are not accurate
predictors of risk or benefits of chemotherapy [18, 117-120]. A validated software
program Adjuvant!Online (AOL) has been developed that projects outcomes at 10 years
to assist oncologists in adjuvant decision-making process. However, AOL is also based
on histopathologic measures.
The 21-gene recurrence score assay (Oncotype DX) produces a “tumor signature”
reflecting tumor biology and risk of relapse [11, 18]. An algorithm produces a continuous
variable known as the “recurrence score” (RS) reflecting prognosis, which ranges from 1
(lower risk) to 100 (higher risk), based on the expressions of the 21 genes isolated from
tumor samples. Women with a score of less than 18 have a low risk of recurrence and
typically have good outcomes from endocrine therapy alone, whereas those with a score
of 31 or more have a high risk of recurrence and gain the largest expected benefit from
the addition of chemotherapy to endocrine therapy. Women with a score between 18 and
30 have an intermediate risk and do not appear to have a large benefit from chemotherapy
but the uncertainty in the estimate cannot exclude a clinically important benefit [11, 25].
The prognostic and predictive value of the RS-assay in women with ER+/PR+ LNESBCwas evaluated in retrospective analyses of the National Surgical Adjuvant Breast
and Bowel Project (NSABP) chemotherapy-tamoxifen trials (B-14 and B-20) [11, 18,
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121] in the United States. It was shown that among ER+/PR+ LN- ESBC patients,
approximately, 51% had a low RS, 22% an intermediate RS, and 27% a high RS [11, 18,
121]. The assay was found to be more accurate than histological measures alone in
predicting the likelihood of breast cancer recurrence (both loco-regional [121] and distant
recurrence [11, 18]) and patient survival within 10 years of initial diagnosis [11], as well
as benefit from adjuvant chemotherapy [11, 121]. Additionally, clinical significance of
the RS-assay has been reported in the Asian population [81].
In 2007 the RS-assay was recommended in the National Comprehensive Cancer Network
and American Society for Clinical Oncology guidelines as “evidence-based” to guide the
use of adjuvant chemotherapy in all women with ER+/ PR+ LN- ESBC [122-123]. Public
coverage of the 21-gene assay is limited and inconsistent across Canada. However, the
use of the test with reimbursement mechanisms is likely increasing. It is available in
Ontario through “out-of-country health services” which requires a request from an
oncologist and pre-approval [124-125]. In 2010 the Ontario Health Technology Advisory
Committee (OHTAC) recommended that the assay be made available “within the context
of a field evaluation” [126]. It is also available in a limited fashion in British Columbia
and Quebec [125]. The test is not widely used and in 2010 less than 1000 patients
received the test across Canada [125] but few field evaluations to establish its impact on
Canadian practice are ongoing in British Columbia and Ontario.
According to the Annual Report Card of the Cancer Advocacy Coalition of Canada, the
RS-assay will cost $CAD 4,000 per patient including all Canadian system expenses
[124]. Previous cost-effectiveness analyses of the RS-assay in women with ER+/ PR+
LN- ESBC in the US [127-128], Japan [129-130], Israel [131] and Canada [132-134]
suggested that it is likely to be cost saving or cost effective in this patient group.
However, findings from studies in Israel [131] and Japan [19-20] cannot be extrapolated
to the Canadian context because of possible variations in clinical practice and different
approaches to pricing and reimbursement. Additionally, analyses from the US [127-128]
and Canada [132-134] did not use all relevant data and suffer from other limitations as
indicated elsewhere [135].
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Generation of recommendations for Canadian clinical practice guidelines regarding the
use of RS-assay requires a comprehensive health economic evaluation of the assay in the
Canadian setting. The purpose of this study was to conduct a cost-effectiveness analysis
of the RS-assay versus current clinical practice (CCP) regarding adjuvant chemotherapy
treatment in women with ER+/ PR+ LN- ESBC from the perspective of the Canadian
healthcare system.

3.3 Methods
3.3.1

Overview of Model-Structure

I developed a decision analytic model (Figure 1) to project the lifetime clinical and
economic consequences of ER+/ PR+ LN- ESBC under two different treatment
strategies. The model begins with a decision to use the RS-assay or to continue with CCP
(Figure 1a). I assumed that each strategy (RS or CCP) classifies patients to three risk
levels (low, intermediate and high) and corresponding treatment regimens (endocrine
therapy plus chemotherapy or endocrine therapy alone). Patients receiving endocrine
therapy alone entered model “E” (Figure 1b) and those receiving chemotherapy plus
endocrine therapy entered model “C” (Figure 1c).
Model “E” simulated monthly transitions among the following four distinct health states:
(1) remission; (2) loco-regional recurrence (LR); (3) distant recurrence (DR); (4) death.
Model “C” simulated monthly transitions among the following five distinct health states:
(1) remission with no chemotherapy-related serious adverse effects (CSAE); (2)
remission with CSAE; (3) LR; (4) DR; (5) death.
I used a lifetime horizon and half cycle correction [136]. Future costs and benefits were
discounted at 5% annually following Canadian guidelines [72]. Data collection and
analysis involving Manitoba administrative databases (including the Manitoba Cancer
Registry, the Hospital Discharge Database, the Physician Claims Database and the Drug
Program Information Network) were approved by the University of Manitoba Health
Research Ethics Board.
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Figure 1. Decision model for early stage breast cancer.
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b Schematic representation of the Markov model structure “E”*‡.
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c Schematic representation of the Markov model structure “C”†‡.

Remission with

LR

no CSAE

DR

Remission with
CSAE

Dead
± The risk classification criteria in the Canadian clinical practice arm was based on the Canadian clinical practice
guidelines for adjuvant systemic therapy for women with node-negative breast cancer [117].
* Patients entering Markov model “E” start the model and remain in the remission state unless they relapse (LR, DR or
Dead).
† Patients entering Markov model “C” start the model in the remission state with no CSAE. Within the first cycle patients
may develop CSAE. These patients will make a transition to the remission state with CSAE. During the first cycle,
patients also may transition to DR, LR and Dead states. After the first cycle, patients may remain in the two remission
states unless they relapse in to LR, DR or Dead.
‡ In both Markov models, patients who developed LR, remain in the LR state or make transition to DR or Dead states.
Patients who developed DR remain in the DR state or make transition to the Dead state. The cycle length was 1 month.
LR, loco-regional recurrence; DR, distant recurrence; CSAE, chemotherapy-related serious adverse effects.
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3.3.2

Risk distribution and transition probabilities

The Manitoba Cancer Registry is a provincial database that contains records for more
than 99.5% of all cancer patients in Manitoba [137]. Information on breast cancer
staging, based on the American Joint Commission on Cancer (version 5), has been
collected for breast cancers diagnosed since January 1995 [138]. I used the Registry to
identify a study cohort consisting of all pre-menopausal (defined as age <50 years) and
post-menopausal (age ≥50 years) women living in Manitoba diagnosed with ER+/ PR+
LN- ESBC (stage I/II) during the period from January 1, 2000 to December 31,
2002.Although data on human epidermal growth factor receptor 2 (HER-2) status were
not collected by the registry during this time frame, the majority of these women are
likely HER-2 negative since women with HER-2 positive are only found in
approximately 10% to 15% of endocrine positive breast cancers such as those in our
study population [139-143]. I used data from women diagnosed during this period so that
a long follow up period would be available. Seven-year follow-up information from the
time of diagnosis was available for each patient. This included breast cancer recurrence
(LR and DR) and treatments (surgery, radiation therapy, endocrine therapy and
chemotherapy). I linked the study cohort identified using the Registry with administrative
data held by Manitoba Health and Healthy Living including the Hospital Discharge
Database, the Physician Claims Database and the Drug Program Information Network.
To protect confidentiality, the linkage in this study was performed, via scrambled health
number, using anonymatized versions of these databases.
To verify that the proportion of women who received adjuvant chemotherapy in our study
cohort would reflect more recent clinical practice regarding adjuvant chemotherapy
administration, I examined a second cohort, consisting of all women diagnosed between
January 1, 2003 and December 31, 2005. I did not find the proportion receiving adjuvant
chemotherapy to differ between the two time periods (chi-square test, level of
significance of 0.05) and thus used the earlier time period with longer follow-up data to
parameterize the model.
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For the CCP model I estimated the risk distribution and proportion receiving
chemotherapy within each risk level (Table 1). According to the Canadian clinical
practice guidelines, risk can be specified on the basis of tumor size, histological or
nuclear grade, and lymphatic and vascular invasion [117]. The Manitoba Cancer Registry
collects this information with the exception of lymphatic and vascular invasion. Given
the significant correlation between tumor size and lymphatic and vascular invasion[144],
I classified pre- and post-menopausal women for this analysis as belonging to three risk
levels (low, intermediate and high risk) on the basis of tumor size and histological or
nuclear grade only. I defined current clinical practice according to the observed
administration of adjuvant therapy in the ER+/ PR+ LN- ESBC cohort during the study
period. I conducted survival analyses using Kaplan-Meier estimates for pre- and postmenopausal women separately, stratified by use of adjuvant chemotherapy, using 7 years
of follow up data from the Manitoba Cancer Registry, and used this information to
estimate all transition probabilities in the CCP Markov models.
For the RS-assay model, I derived the risk distribution and monthly transition
probabilities from remission to LR, DR and Death over 10 years within each risk level
from retrospective analyses of the NSABP chemotherapy-tamoxifen trials (B-14 and B20) (Table 1) [11, 121]. Investigators from the B-14 and B-20 studies provided Kaplan
Meier curves for LR, DR and death events stratified by risk level. To account for
menopausal status, I adjusted all transition probabilities derived from these summary
statistics based on corresponding risk ratios (for LR, DR and death) comparing pre- to
post-menopausal women derived from our studied ESBC cohort. The risk ratios were
weighted using the menopausal status balance reported in the B-14 and B-20 trials [11,
121].
There is still uncertainty as to whether chemotherapy is necessary for women with

intermediate risk. Reported usage in this group varies, including estimates of 56% [145],
50% [146], 47% [147], 38% [148], 33% [131], and 26% [149]. In the base case I
assumed that 50% of women in the intermediate risk group would receive adjuvant
chemotherapy.
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There is no data suggesting that outcomes after first relapse are affected by the primary
adjuvant therapy received [150]. Thus, I assumed that transition probabilities following
first relapse in the RS-assay model would be the same as those in the CCP model.
To extrapolate beyond the follow-up period of the ESBC cohort and the clinical trials
used for this study, I assumed that the observed average monthly transition probabilities
from remission to LR, DR and Death during the last observed year of follow-up would be
constant over the extrapolated lifetime. I used female age-adjusted life tables for
Manitoba to adjust the probabilities from remission to death in order to account for the
incremental mortality risk over the extrapolated time [151].
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Table 1. Parameter estimates and sources.

Variables

Pre-menopausal
Women
Base
Range tested
case
in sensitivity
value
analyses

Post-menopausal
Women
Base
Range tested
case
in sensitivity
value
analyses

Duration

Distribution
used in PSA†

Source

Dirichlet

MCR

Risk classification by CCP (%)
High risk
Chemotherapy-treated women
Intermediate risk

21.1

15.8 – 32.6

22.3

18 – 27

100

85.1 – 100

53.8

43 – 64.4

Beta

MCR and PC

72.6

62.9 – 80.6

52.3

47 – 57.5

Dirichlet

MCR

65.2

53.4 – 75.4

14.2

9.9 – 20

Beta

MCR and PC

Low risk

6.3

0 – 10

25.4

21.2 – 30.2

Dirichlet

MCR

Chemotherapy-treated women

16.7

10 – 20

3.4

0 – 10

Beta

MCR and PC

69

60 – 83

19

13 – 27.7

High risk

27.7

22.9– 33.1

23.1

18.7 – 28.3

Dirichlet

[11]

Chemotherapy-treated women

100

90 – 100

100

90 – 100

Beta

[11]

Intermediate risk

19.5

15.4 – 24.4

21.5

17.1 – 26.5

Dirichlet

[11]

Chemotherapy-treated women

Overall chemotherapy-treated women by CCP (%)

MCR and PC

Risk classification by RS-assay (%)

Chemotherapy-treated women

50

0 – 100

50

0 – 100

Beta

[131, 148-149, 152]

52.6

46.9 – 58.3

55.4

49.7 – 61

Dirichlet

[11]

0

0 – 10

0

0 – 10

Beta

Overall chemotherapy-treated women by RS-assay (%)

37.5

30 – 47.8

33.8

27 – 44.3

Chemotherapy-related serious adverse effects (%)

2.5

0 – 10.6

4

0 – 12.3

Beta

[11]
[11, 131, 148-149,
152]
MCR and HA

0.85

-20%

0.783

-20%

6 months

Beta

[153-155]

0.623

-20%

0.577

-20%

6 months

Beta

[153-155]

Low risk
Chemotherapy-treated women

Health-State Utilities‡
Remission state
Remission on chemotherapy regimen with
minor or no toxicity
Remission on chemotherapy regimen with
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major toxicity
Remission after chemotherapy regimen

0.872

-20%

0.808

-20%

Life

Beta

[155-156]

Remission on hormonal therapy

0.881

-10% – +10%

0.816

-10% – +10%

60 months

Beta

[153-155]

Remission after hormonal therapy

0.89

-10% – +10%

0.824

-10% – +10%

Life

Beta

[153-155]

Loco-regional recurrence, under treatment

0.623

-10% – +10%

0.577

-10% – +10%

12 month

Beta

[150, 153-155]

Loco-regional recurrence, after treatment

0.757

-10% – +10%

0.700

-10% – +10%

Life time

Beta

[150, 153-155]

Distant recurrence

0.445

-10% – +10%

0.412

-10% – +10%

Life time

Beta

[150, 153-155]

Death state

0

0

Cost associated with remission (per month), $
First year after diagnosis with ESBC
Cost of surgerya

3390

3000 – 3780

3642

3384 – 3900

One time

LogNormal

PC. HA and CL

3410

2737 – 4252

3027

2430 – 3776

One time

LogNormal

PC and CL

12.4

11.6 – 13.2

12.4

11.6 – 13.2

12 months

LogNormal

DPIN

Aromatase inhibitors

156

120 – 193

12 months

LogNormal

DPIN

Aromatase +tamoxifen

72

62 – 81

12 months

LogNormal

DPIN

LogNormal

CL

LogNormal

PC

b

Cost of radiation therapy

Cost of endocrine therapyc
Tamoxifen

d

Cost of chemotherapy

Nursing, overhead and administration costs

317.6

Related physician costs

23.4

317.6
21.5 – 25.2

23.4

21.5 – 25.2

During
chemotherapy
During
chemotherapy

Chemotherapy regimen options
CMF

478

823

5 months

LogNormal

MCR

AC

806

1918

3 months

LogNormal

MCR

924

1270

5 months

LogNormal

MCR

2455

2800

FAC
TAC
e

Weighted average cost of chemotherapy regimens

5 months

LogNormal

MCR

5 months

LogNormal

MCR

First three months on chemotherapy

1142

1099

3months

LogNormal

MCR

Next

419

432

2months
During
chemotherapy

LogNormal

MCR

LogNormal

PC, HA and CL

Cost of CSAE

f

1263

978 – 1581

1,750

1376-2168

33

Surveillanceg
Low risk

79

47 – 111

74

62 – 85

12 months

LogNormal

PC

Intermediate risk

93

76 – 108

66

60 – 68

12 months

LogNormal

PC

High risk

106

78 – 133

77

69 – 82

12 months

LogNormal

PC

12.4

11.6 – 13.2

After first year of diagnosis with ESBC
Cost of endocrine therapyc
Tamoxifen

12.4

11.6 – 13.2

48 months

LogNormal

DPIN

Aromatase inhibitors

156

120 – 193

48 months

LogNormal

DPIN

Aromatase +tamoxifen

72

62 – 81

48 months

LogNormal

DPIN

33

30 – 54

Life time

LogNormal

PC

g

Surveillance

Low risk

39

18 – 59

Intermediate risk

35

32– 40

45

38 – 53

Life time

LogNormal

PC

High risk

102

65 – 126

39

32 – 45

Life time

LogNormal

PC

3522

889 – 7280

2806

1068 – 3111

One time

LogNormal

PC, HA and CL

1098

878 – 1371

2120

1695 – 2651

One time

LogNormal

PC, HA and CL

12.4

11.6 – 13.2

12.4

11.6 – 13.2

12 months

LogNormal

DPIN

Aromatase Inhibitors

156

120 – 193

12 months

LogNormal

DPIN

Sequential aromatase → tamoxifen

72

62 – 81

12 months

LogNormal

DPIN

Cost associated with LR (per month), $
First year after LR
Cost of Surgerya
b

Cost of Radiation therapy

Cost of endocrine therapyc
Tamoxifen

d

Cost Chemotherapy

278

181 – 619

311

200 – 688

5 months

LogNormal

PC and CL

Surveillance during first yearg

118

48 – 189

123

64 – 179

12 months

LogNormal

PC

12.4

11.6 – 13.2

12.4

11.6 – 13.2

48 months

LogNormal

DPIN

Aromatase Inhibitors

156

120 – 193

48 months

LogNormal

DPIN

Sequential aromatase → tamoxifen

72

62 – 81

48 months

LogNormal

DPIN

78

18 – 139

Life time

LogNormal

PC

After first year of LR
Cost of endocrine therapyc
Tamoxifen

Surveillance after first year of LR

g

98

33 – 162

34

Cost associated with DR (per month), $
First year after DR
Hospitalization cost

841

138 – 253

1569

185– 3177

12 months

LogNormal

Physicians cost

247

64 – 431

353

205 – 501

12 months

LogNormal

PC

Drugs cost

19

5 – 34

83

29 – 134

12 months

LogNormal

DPIN

Hospitalization cost

1293

146 – 3014

783

72 – 1618

Life time

LogNormal

HA and CL

Physicians cost

204

86 – 322

183

62 – 337

Life time

LogNormal

PC

Drugs cost

52

5 – 121

100

33 – 167

Life time

LogNormal

DPIN

HA and CL

After first year of DR

† Beta distribution was used for other probability parameter estimates not included in this table.
‡ The baseline utility for post-menopausal women aged 50 to 80 was 0.824 and for premenopausal women aged 20 to 49 was 0.89[155]. I derived utilities for each state
by multiplying these baseline utility values by utility estimates for women with breast cancer [150, 153, 156-157], consistent with methodology as described by Fryback
[154].
a
Cost of breast cancer surgery: I used the Hospital Discharge Database and the Physician Claims Database to estimate the mean cost of hospitalization due to any breast
cancer surgery (including one day hospitalization and using the ICD-9-CM procedure codes for a hospital abstract) within one year after diagnosis with ESBC and LR by
menopausal status.
b
Cost of radiation therapy: Cost of radiation therapy included cost of radiation therapy–related physician claims in addition to administrative cost. I used the Physician
Claims Database to estimate the mean cost of radiation therapy–related physician claims (using the tarrif code for a medical claim) within one year after diagnosis with
ESBC and LR by menopausal status. Administrative costs were derived from the cost list for Manitoba health services.
c
Cost of endocrine therapy: I used the Drug Program Information Network to estimate the mean cost of tamoxifen and aromatase inhibitors by menopausal status (using
the drug identification number for a drug claim) within the time periods, between diagnosis with ESBC and before any relapse, and diagnosis with LR and before any
relapse.
d
Cost of chemotherapy: Nursing, overhead and administration costs were derived from the cost list for Manitoba health Services. I used the Physician Claims Database to
estimate the mean cost of chemotherapy–related physician claims costs (using the tariff code for a medical claim) within one year after diagnosis with ESBC and LR by
menopausal status. Chemotherapy regimens costs were estimated based on the market prices as of May 2010.
e
Weighted average cost of adjuvant chemotherapy regimens: I calculated the average cost of adjuvant chemotherapy regimens weighted to the observed proportion use of
anthracyclines and taxanes by menopausal status. Weighted average cost of adjuvant chemotherapy regimens = proportion of women received non-anthracycline
containing adjuvant chemotherapy × cost of CMF + proportion of women received anthracycline containing adjuvant chemotherapy (no added taxanes) × cost of AC +
proportion of women received anthracyclines and taxanes containing adjuvant chemotherapy × cost of TAC.
f
Cost of CSAE: I used the Hospital Discharge Database and the Physician Claims Database to estimate the mean cost associated with hospitalizations due to any of the
eight diagnoses which were considered CSAE among women who develop CSAE. I stratified the analysis by menopausal status.
g
Cost of surveillance: I defined the cost of breast cancer surveillance as the incremental cost of health care utilization (medical claims)after diagnosis with ESBC versus
the time before diagnosis. I used the Physician Claims Database to collect medical claims for both post- and pre-menopausal women, within 3 years before and 7 years
after diagnosis with ESBC. I estimated the mean cost of medical claims by menopausal status within 3 years before diagnosis in order to reflect the usual cost of health
care utilization. I calculated the incremental mean cost of health care utilization by menopausal status during the period from diagnosis with ESBC and before any relapse
(excluding cost of claims related to surgery, radiation therapy, chemotherapy and CSAE) stratified by the time following diagnoses (first year versus later). Similarly, I
calculated the incremental mean cost of health care utilization by menopausal status after LR.
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PSA= probabilistic sensitivity analysis; MCR= Manitoba Cancer Registry: PC= physician claims; HA= hospital abstracts; CL= cost list for Manitoba health services;
DPIN=Drug Program Information Network records; ESBC= early stage breast cancer; LR, loco-regional recurrence; DR= distant recurrence; CMF= 6 cycles of
cyclophosphamide, methotrexate, 5-fluorouracil; AC= 4 cycles of doxorubicin, cyclophosphamide; FAC=6 cycles of fluorouracil, doxorubicin, cyclophosphamide;
TAC=6 cycles of docetaxel, doxorubicin, cyclophosphamide; CCP= current clinical practice.
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Table 2. Proportion of patient population receiving adjuvant chemotherapy by diagnosis time period and menopausal status.
Diagnosis time
period

2000−2002
2003−2005
† Chi-square test.

No. of women diagnosed with ER+ or PR+
LN- ESBC

No. of women received adjuvant chemotherapy (%)

Pre-menopausal
women

Post-menopausal women

Pre-menopausal
women

109

389

74 (69)

106

506

71 (67)

2000-2002
vs.
2003-2005
ρ value†
.88

Post-menopausal
women
73 (18.8)
90 (17.7)

2000-2002
vs.
2003-2005
ρ value†
.7
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3.3.3

Adjuvant Chemotherapy Regimens

In Canada, from 2000-2002, two adjuvant chemotherapy regimens were recommended
for women with ER+/ PR+ LN- ESBC: (1) 6 cycles of cyclophosphamide, methotrexate,
5-fluorouracil (CMF) or (2) anthracycline-containing chemotherapy regimen such as 4
cycles of doxorubicin (Adriamycin), cyclophosphamide (AC) or 6 cycles of 5fluorouracil, doxorubicin, cyclophosphamide (FAC) [117]. Four cycles of AC has been
used preferentially as a component of chemotherapy regimens for the adjuvant treatment
of ESBC [158]. Recently, chemotherapy regimens containing taxanes, such as 6 cycles of
docetaxel, doxorubicin, cyclophosphamide (TAC), have been recommended for the LNESBC population [159].
The majority of adjuvant chemotherapy-treated women in our study cohort received
anthracycline-containing adjuvant chemotherapy regimens (Table 2). Information on
specific chemotherapy agents (e.g. CMF, AC, FAC, and TAC) was not available. I
assumed patients who received non-anthracycline-containing adjuvant chemotherapy
regimens received 6 cycles of CMF; that patients who received anthracycline-containing
adjuvant chemotherapy regimens with no added taxanes received four cycles of AC; and
that patients who received anthracycline and taxane-containing adjuvant chemotherapy
regimens received 6 cycles of TAC. Thus, in the base case analysis, I used the weighted
average cost of CMF, AC and TAC.
Anthracycline-containing regimens may have a survival advantage compared to CMF
regimens [160]. However, other studies showed anthracycline-containing regimens to
have equivalent clinical outcomes compared to CMF regimens, particularly in women
with favourable prognostic features (LN-, ER+/PR+) such as our study cohort [117, 161162]. Thus, in sensitivity analysis I considered each of the CMF, AC, FAC and TAC
regimens separately as the standard adjuvant chemotherapy regimen for women with
ER+/ PR+ LN- ESBC.
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3.3.4

Adjuvant chemotherapy-related Serious Adverse
Effects (CSAE)

I defined CSAE as hospitalization for any of the following eight diagnoses (as defined by
their ICD-9-CM diagnosis and procedure codes)occurring within one year of diagnosis
with ESBC: 1) abnormal electrolytes or dehydration; 2) constitutional symptoms and
nonspecific symptoms associated with therapy; 3) nausea, emesis, and diarrhea; 4)
infection and fever; 5) malnutrition; 6) anemia and red cell transfusion; 7) neutropenia or
thrombocytopenia; 8) deep venous thrombosis or pulmonary embolus[163-164]. These
diagnoses were selected based on their association with chemotherapy in previous
clinical trials[116]. I estimated the incremental rate of occurrence of CSAEs from the
frequency of occurrence of these ICD-9 codes in hospital abstracts of adjuvant
chemotherapy recipients versus non-recipients, stratified by menopausal status and
adjusting for comorbidity indices using the method developed by Charlson et al
excluding cancer diagnoses[165].

3.3.5

Costs

Treatment costs, including surgery, radiation therapy, chemotherapy, endocrine therapy,
surveillance, and CSAE, are all publicly funded in Manitoba and are thus recorded in the
administrative databases. For each patient in the studied cohort I gathered all treatment
costs for the first 7 years following diagnosis with primary breast cancer (Table 1). I used
this to estimate the cost per unit time in each Markov state.

3.3.6

Utilities

The baseline utility for post-menopausal women aged 50 to 80was 0.824 and for
premenopausal women aged 20 to 49 was 0.89, based on representative values for the
U.S. population [155]. I derived utilities for each health state by multiplying these
baseline utility values by utility estimates for women with early-stage breast cancer [150,
153-154, 156-157] (Table 1). I performed sensitivity analysis on the utility values after
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chemotherapy to account for potential long term side effects of primary adjuvant
chemotherapy [166].

3.4 Results
Patient, tumor, treatment and event characteristics of the study cohort are summarized in
Table 2. There were 109 pre-menopausal and 389 post-menopausal women diagnosed
with ER+/ PR+ LN- ESBC in Manitoba from January 1, 2000 to December 31, 2002. The
median age was 44 years (range 29-49 years) in pre-menopausal women and 62 years
(range 50-88) in post-menopausal women. All pre- and post-menopausal women received
surgery (mastectomy or breast-conserving surgery) for their primary breast cancer.
Adjuvant therapy including radiation therapy, endocrine therapy (tamoxifen or aromatase
inhibitors) and chemotherapy were administered in 63%, 81% and 69% of premenopausal women, respectively, and in 52%, 79% and 19% of post-menopausal
women, respectively.
In pre-menopausal women, the RS-assay led to an increase of 0.05 QALY per person and
decrease in cost of $50 per person resulting in a cost saving compared to CCP. In postmenopausal women, the RS-assay led to an increase of 0.062 QALY per person and an
increase in cost of $3,700 per person, resulting in an incremental cost effectiveness ratio
(ICER) of $ 60,000 per QALY gained compared to CCP.
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Table 3. Characteristics of 489 patients diagnosed during the time period of 2000 to 2002 with ER+ or PR+ 1-3 LN+ ESBC stratified
by menopausal status and risk of recurrence using Canadian clinical practice guidelines.
Pre-menopausal women (n=109)

Characteristic
Age ( years)
Mean (range)
<40
40 – 49
50 – 64
≥65
Primary tumor size – no. of women (%)
<2 cm
2-5 cm
>5 cm
Receptor status – no. of women (%)
ER+ and PRER- and PR+
ER+ and PR+
Tumor grade – no. of women (%)
1
2
3
Unknown
Stage
I
IIA
IIB
With Breast-surgery‡ – no. of women (%)
Breast-conserving surgery
Mastectomy

ρ
value†

Post-menopausal women (n=389)

Low risk*
(n=11)

Intermedi
ate risk*
(n=78)

High risk*
(n=20)

Overall
(n=109)

Low risk*
(n=115)

Intermediat
e risk*
(n=196)

High
risk*
(n=78)

Overall
(n=389)

41.8
(30 – 49)
3 (27.3)
8 (72.7)
―
―

43.6
(29 – 49)
17 (21.8)
61 (78.2)
―
―

42.7
(33-49)
4 (20)
16 (80)
―
―

43
(29-49)
24 (22)
85 (78)
―
―

63.4
(50 -85)
―
―
64 (55.7)
51 (44.3)

64
(50 – 88)
―
―
111 (56.6)
85 (43.4)

61.8
(50 -86)
―
―
53 (68)
25 (32)

63
(50-88)
―
―
228 (58.6)
161 (41.4)

11 (100)
0
0

51 (65.4)
27 (34.6)
0

7 (35)
11 (55)
2 (10)

69 (63.3)
38 (34.9)
2 (1.8)

115 (100)
0
0

117 (59.7)
79 (40.3)
0

17 (21.8)
55 (70.5)
6 (7.7)

260 (66.8)
123 (31.7)
6 (1.5)

.78

0
0
11 (100)

11 (14.1)
4 (5.2)
63 (80.7)

7 (35)
3 (15)
10 (50)

18 (16.6)
7 (6.4)
84 (77)

25 (21.7)
1 (0.9)
89 (77.4)

54 (27.5)
4 (2.1)
138 (70.4)

30 (38.5)
6 (7.7)
42 (53.8)

109 (28)
11 (2.8)
269 (69.2)

.016

6 (54.5)
0
0
5 (45.5)

14 (18)
50 (64.1)
5 (6.4)
9 (11.5)

1 (5)
5 (25)
14 (70)
0

21 (19.3)
55 (50.5)
19 (17.4)
14 (12.8)

89 (77.4)
0
0
26 (22.6)

17 (8.7)
160 (81.6)
6 (3)
13 (6.7)

1(1.3)
21 (26.9)
53 (68)
3 (3.8)

107 (27.5)
181 (46.5)
59 (15.2)
42 (10.8)

.37

11 (100)
0
0
11 (100)
8 (72.7)
3 (27.3)

55 (70.5)
23 (29.5)
0
78 (100)
51 (65.4)
27 (34.6)

7 (35)
11 (55)
2 (10)
20 (100)
9 (45)
11 (55)

73 (67)
34 (31.2)
2 (1.8)
109 (100)
68 (62.4)
41 (37.6)

115 (100)
0
0
115 (100)
65 (56.5)
50 (43.5)

145 (74)
51 (26)
0
196 (100)
113 (57.7)
83 (42.3)

21 (26.9)
51 (65.4)
6 (7.7)
78 (100)
29 (37.2)
49 (62.8)

281 (72.2)
102 (26.2)
6 (1.6)
389(100)
207 (53.4)
182 (46.6)

.56

.08
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With Radiotherapy‡ – no. of women (%)
With Endocrine therapy‡ – no. of women (%)
Tamoxifen
Aromatase inhibitors + tamoxifen
Aromatase inhibitors
Unknown type
With adjuvant Chemotherapy‡ – no. of women (%)
No anthracyclines
Anthracyclines, no taxanes
Anthracyclines and taxanes
Unknown type
Loco-regional recurrence event – no. of women (%)
Distant recurrence event – no. of women (%)
Deaths – no. of women (%)
Charlson co-morbidity score mean (SE, range)¶
Charlson co-morbidity score – no. of women (%)¶
0
1
2
3
4
5
6

7 (63.6)
5 (45.4)
5 (100)
0
0
0
3 (27.3)
0
3 (100)
0
0
0
0
0

51 (65.4)
65 (83.3)
49 (75.4)
13 (20)
1 (1.5)
2 (3)
51 (65.4)
17 (33.3)
29 (56.9)
2 (3.9)
3 (5.9)
4 (5.1)
3 (3.8)
3 (3.8)

11 (55)
18 (90)
13 (72)
4 (22)
0
1 (5.5)
20 (100)
5 (25)
12 (60)
2 (10)
1 (5)
2 (10)
3 (15)
3 (15)

0

0.10

0.05

11 (100)
0
0
0
0
0
0

71 (91)
6 (7.7)
1 (1.3)
0
0
0
0

19 (95)
1 (5)
0
0
0
0
0

69 (63.3)
88 (81)
67 (76.1)
17 (19.3)
1 (1.2)
3 (3.4)
74 (69)
22 (35.6)
44 (54.8)
4 (4.1)
4 (5.5)
7 (6.4)
6 (5.5)
6 (5.5)
0.08
(0.03, 0–2)

62 (54)
91 (79.1)
61 (67)
25 (27.5)
5 (5.5)
0
3 (2.6)
1
1
0
1
1 (.86)
2 (1.7)
10 (8.6)

109 (55.6)
165 (84.1)
104 (63)
48 (29)
10 (6)
3 (2)
28 (14.3)
9 (32.1)
16 (57.1)
0
3 (10.8)
2 (1)
10 (5.1)
31 (15.8)

30 (38.5)
53 (67.9)
31 (58.5)
18 (34)
3 (5.7)
1 (1.8)
42 (53.8)
16 (38.1)
23 (54.8)
3 (7.1)
0
10 (12.8)
14 (17.9)
22 (28.2)

0.11

0.20

0.19

101(92.6)
7 (6.4)
1 (1)
0
0
0
0

104 (90.4)
9 (7.8)
2 (1.8)
0
0
0
0

171 (87.3)
18 (9.2)
3 (1.5)
2 (1)
0
1 (.5)
1 (.5)

69 (88.4)
6 (7.7)
1 (1.3)
1 (1.3)
1 (1.3)
0
0

201 (51.7)
309 (79.4)
196 (63.4)
91 (29.5)
18 (5.8)
4 (1.3)
73 (18.8)
26 (29.7)
40 (59.5)
3 (5.4)
4 (5.4)
13 (3.3)
26 (6.7)
63 (16.2)
0.18
(0.03, 0–6)
344 (88.4)
33 (8.4)
6 (1.5)
3 (.8)
1 (.3)
1 (.3)
1 (.3)

.03
.76
.02

< .0001
.88

.14
.65
.004
.028
.86

*Categorization of a patient’s risk for recurrence as low, intermediate, or high was according to the Canadian clinical practice guidelines [117]. Low risk: Post-menopausal women with primary tumor size <
2cm and tumor grade = 1; pre-menopausal women with primary tumor size < 1cim and tumor grade =1. High risk: All women with tumor size >3cm, or women with tumor size ≥ 1cm and ≤ 3cm with tumor
grade = 3. Intermediate risk: Post-menopausal women with tumor size < 2cm and tumor grade > 1, or tumor size ≥ 2cm and < 3cm and tumor grade = 1 or 2; premenopausal women with tumor size < 1cm and
tumor grade >, or tumor size ≥ 1cm and < 3cm and tumor grade=1 or 2. Given the significant correlation between tumor size, lymphatic and vascular invasion [144], and tumor grade[167], lymphatic and
vascular invasion was not used in categorizing patients’ risk because the Manitoba cancer registry does not collect this information and 52 patients ‘risk for recurrence was categorized on the basis of tumor
size only because their tumors size < 3cm with undetermined tumors grade.
†The p-value was calculated for overall pre- vs. overall post-menopausal women. Fisher’s exact and chi-square tests were used for binary and categorical variables respectively. Distributions of continuous
variables were summarized by their means and standard errors and compared using t-tests.
‡Women were defined as having received any of these treatments for their primary breast cancer if the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) procedure
code or the Canadian Classification of Health Interventions (CCI) procedure code of any of these treatments was found before any recurrence, second primary cancer or death within one year of diagnosis with
ESBC.
¶ Co-morbid diagnoses were considered present if they were found during one year before and 6 months after the diagnosis with primary breast cancer.
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3.5 Sensitivity Analysis
In the base case I compared the RS assay versus CCP when weighted average cost of
CMF, AC and TAC was used. I considered each of CMF, AC, FAC and TAC regimens
separately as the standard adjuvant chemotherapy regimen for women with ER+/ PR+
LN- ESBC in sensitivity analysis. In premenopausal women, the RS-assay stayed cost
saving with each of CMF, AC, FAC and TAC regimens. In post-menopausal women, the
RS-assay had an ICER of $59,800 per QALY gained with CMF, $58,200 per QALY
gained with AC, $65,000 per QALY gained with FAC and $83,100 per QALY gained
with TAC. The utility during chemotherapy and the rates and costs of CSAE did not
substantially influence the results with any regimen.
I performed threshold analyses on the proportion of chemotherapy-treated women
classified as being in the intermediate risk group by the RS-assay, on the risk of relapse
in the RS-assay model and other parameters found to influence our base case analyses
(Tables 4 and 5). Among pre-menopausal women, the RS-assay generated negative
incremental cost and effect (the RS-assay led to decrease in cost and effect) and when
fewer than 43% of women in the RS-assay intermediate risk group received adjuvant
chemotherapy. Among postmenopausal women, the RS-assay was dominated by CCP
when fewer than 31% of women in the RS-assay intermediate risk group received
adjuvant chemotherapy. When the absolute risk of relapse in the RS-assay model
increased by approximately 2% in either pre- or post-menopausal women, the RS-assay
would be dominated by CCP or associated with negative incremental cost and effect.
I also performed a probabilistic sensitivity analysis (Figure 2) comparing the RS-assay
versus CCP. I simultaneously varied all parameters (probabilities, utilities and costs)
using appropriate distributions (Table 1). In pre-menopausal women, using a willingneess
to pay threshold of $100,000 per QALY gained, I found that the RS-assay was the
prefered strategy in 54% of simulations (Figure 2 a and b). In post-menopausal women, I
found that the RS-assay was the prefered strategy in 62% of simulations (Figures 2 c and
d).
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Table 4. Summary of important one-and two way sensitivity analysesa.
Interpretation of the incremental impact of the RS-assay compared to CCP
Negative
cost and
effect

Cost saving

ICER in the
range
0 to 20,000
$/QALY
gained

Chemotherapy treated women in intermediate
risk group by the RS-assay (0% to 100%)

0% to 42%

43% to 63%

64% to 100%

Change in absolute risk of relapsebin the RSassay model
(-10% to +10%)

> +1.8%

≤ +1.8%

Variable (range tested)

Lower limit cost of
recurrencec
Baseline cost of
recurrencec
Upper limit cost of
recurrencec
Change in utility following adjuvant
chemotherapy (-10% to +10%)

Change in utility of
recurrencec
(-10% to +10%)

≤ +2.2%
> +3%

≤ +3%

> +3%

≤ +3%

> +1%

≤ +1%

ICER in the range
20,000 to 100,000
$/QALY
gained

ICER in the
range
>100,000
$/QALY
gained

Dominated

+2.3% to +3.4%

+3.5% to +4%

≥ +4%

CMF= 6 cycles of cyclophosphamide, methotrexate, 5-fluorouracil; AC= 4 cycles of doxorubicin, cyclophosphamide; CCP= current clinical practice.
a
Values in the table show how the incremental impact of the RS-assay compared to CCP changes, over 6 significant ranges, depending on the values of certain key
parameters. For example, if between 43-63% of women identified as intermediate risk by the RS-assay were to receive chemotherapy, then the RS-assay would be cost
saving relative to CCP; if this proportion is 64% or greater, then the RS-assay has an ICER between 0 and $20,000 / QALY gained.
b
Relapse includes loco-regional recurrence, distant recurrence and death due to any cause.
c
Recurrence includes loco-regional and distant recurrences.
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Table 5. Summary of important one-and two way sensitivity analysesa.

Interpretation of the incremental impact of the RS-assay compared to CCP

Variable (range tested)
Chemotherapy treated women in
intermediate risk group by the RS-assay
(0% to 100%)
Change in absolute risk of relapseb in
the RS-assay model
(-10% to +10%)
Lower limit
cost of
recurrencec
Change in utility of
Baseline cost
recurrencec
of recurrencec
(-10% to +10%)
Upper limit
cost of
recurrencec
Change in utility following adjuvant
chemotherapy (-10% to +10%)

Negative
cost and
effect

Cost
savings

ICER in the
range
0 to 20,000
$/QALY
gained

ICER in the range
20,000 to 100,000
$/QALY
gained

ICER in the
range
> 100,000
$/QALY
gained

Dominated

86% to 100%

42% to 85%

32% to 41%

0% to 31%

< -3%

-3 % to +0.9%

+1% to +2%

> +2%

< +9%

≥ +9%

-10% to +10%
-10% to +10%
> 4.5%

-0.8% to +4.5%

-2.4% to -0.9%

≤ -2.5%

CMF= 6 cycles of cyclophosphamide, methotrexate, 5-fluorouracil; AC= 4 cycles of doxorubicin, cyclophosphamide; CCP= current clinical practice.
a
Values in the table show how the incremental impact of the RS-assay compared to CCP changes, over 6 significant ranges, depending on the values of certain
key parameters. For example, if between 43-63% of women identified as intermediate risk by the RS-assay were to receive chemotherapy, then the RS-assay
would be cost saving relative to CCP; if this proportion is 64% or greater, then the RS-assay has an ICER between 0 and $20,000 / QALY gained.
b
Relapse includes loco-regional recurrence, distant recurrence and death due to any cause.
c
Recurrence includes loco-regional and distant recurrences.

45

Figure 2. Incremental cost-effectiveness scatterplot and acceptability curve of RS-assay-guided therapy versus
CCP-guided therapy for pre- and post-menopausal women. Sampling distributions and summary estimates of
cost, efficacy, and variance were based on 1000 replicates.
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3.6 Discussion
I developed a decision-analytic model to evaluate the cost effectiveness of the RS-assay
versus CCP in ER+/ PR+ LN- ESBC. In the base case I estimated that the RS-assay
generated cost savings in pre-menopausal women and has an ICER of $60,000 per QALY
gained in post-menopausal women.
In Canada, an ICER threshold of $100,000 per QALY gained has been suggested as
representing “weak evidence for adoption and appropriate utilization” [62, 72], although
there is no evidence that any Canadian decision-making body has formally implemented
this threshold [168]. The ICERs of the RS-assay in post-menopausal women were within
ranges of a number of cancer treatments that have recently been approved in Canada. For
instance, sorafenib has an estimated ICER of $75,821 per life year gained for the
treatment of hepatocellular carcinoma and has been approved for funding in Ontario
through the Exceptional Access Program [169]. Sunitinib has been funded in all
Canadian provinces for first-line treatment of metastatic renal-cell carcinoma with an
ICER of $144,000 per QALY gained [170].
Previous cost-effectiveness analyses of the RS-assay in ER+/ PR+ LN- ESBC population
have several limitations and may not be applicable in the Canadian context. One study
[127] did not incorporate results from NSABP B20 [11], which established the
relationship between the RS-assay and the benefit from using chemotherapy. Another two
studies [128-129] included results from NSABP B20 [128]; however, the treatment
strategies that they compared (tamoxifen alone for everyone and tamoxifen and
chemotherapy for everyone) do not reflect observed clinical practice in Canada (Table 2).
Other studies from Israel [131] and Japan [130] did not incorporate all early stage breast
cancer complications such as local or regional recurrence. Three recent studies [132-134]
were conducted from the Canadian health care payer’s perspective; however, the first
analysis [132] did not address all the limitations mentioned above, and modeling the
current experience of ER+/ PR+ LN- ESBC population with regard to survival in the
three analyses [132-134] was not based on Canadian data and real world clinical practice.
In all studies there was no differentiation in adjuvant chemotherapy practice between pre-
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and post-menopausal women as recommended by Canadian guidelines [117], whereas I
observed differences in clinical practice for these two groups (Table 2).
Adjuvant chemotherapy is a widely recommended treatment in ER+/ PR+ LN- ESBC
[124]. Thus, some have suggested that large cost savings can be expected by avoiding
chemotherapy treatment in 25% to 35% of patients based on the results of the RS-assay
[124]. Our analysis suggests that cost savings may be possible in pre-menopausal women,
due the wide use of chemotherapy in this group, but would likely not occur with postmenopausal women with ER+/ PR+ LN- ESBC. According to our analysis, the RS-assay
results may increase chemotherapy treatment in aproximetly15% of post-menopausal
women with ER+/ PR+ LN- ESBC and would generate favorable QALYs gained and
increase costs over CCP in this patient population. This scenario is likely due to both the
ability of the RS-assay to better distinguish patients who likely benefit from
chemotherapy compared to CCP and the possibility that many of post-menopausal
women in CCP are reluctant to undergo chemotherapy and would be persuaded of its
importance because of the test results [171].
In sensitivity analysis I addressed the economic impact of uncertainty in clinical
guidelines for intermediate-range RS-assay values(18-30) [172]. Our analysis
demonstrated that the ability of the RS-assay to guide treatment decisions in the
intermediate risk group likely would be important in determining whether the RS-assay
will be a cost-effective use of resources. If fewer than 43% of pre-menopausal and 31%
of post-menopausal women identified as intermediate risk by the RS-assay received
adjuvant chemotherapy, then the RS-assay had negative health effects compared to CCP.
An ongoing prospective clinical trial will further assess the predictive value of the assay
in women in the intermediate risk group and will be helpful in verifying our results [25].
However, findings from this trial will not be available for 5 to 10 years whereas an
adoption decision will need to be made prior to having the results of this trial.
Our analysis has several limitations. First, there are limits to what can be ascertained
through administrative data. Although the Manitoba Cancer Registry is a highly accurate
source of information about breast cancer [137], errors in coding can result in incorrect or
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unrecorded procedures. However, wherever possible I cross validated across databases.
For instance, information on breast cancer treatments including surgery, radiation
therapy, endocrine therapy and chemotherapy can be found in both the Manitoba Cancer
Registry and the administrative databases held by Manitoba Health and Healthy Living.
Second, validation data for the 21-gene assay was based on retrospective analyses of the
NSABP chemotherapy-tamoxifen trials (B-14 and B-20) conducted in the United States
[11, 121]. Thus, survival outcomes by the RS-assay may not reflect the experience of the
ER+/PR+ LN- ESBC identified in Manitoba due to possible differences in patient and
tumor characteristics and treatments. Results from future prospective analyses of the
assay in real-world clinical practice and in Canadian settings can be used to update our
model and verify our results. Third, there is still uncertainty as to whether chemotherapy
is necessary for women who fall in the intermediate risk group by the RS-assay [25].
Fourth, newer third generation anthracycline-taxane regimens have different costs and
slightly better efficacy so analysis with such data would be more applicable to the current
practice landscape. In addition, our analysis did not account for growing data on long
term side effects of primary adjuvant chemotherapy such as cardiomyopathy, neuropathy,
and leukemia [166]. Finally, although several studies have found that clinical practice
patterns and therapies employed in the selected time periods in Manitoba reflect practice
in other jurisdictions in Canada [173-175], differences in clinical practice for women
with ER+/PR+ LN- ESBC and its associated costs across Canadian provinces may still
exist.

3.7 Conclusion
I compared the RS-assay versus current clinical practice in ER+/ PR+ LN- ESBC for
both pre- and post-menopausal women. I found that it is likely to be cost-saving for premenopausal women and to have an ICER that is within ranges of a number of cancer
treatments recently approved for funding in Canada for post-menopausal women.
Validation of the assay in real-world clinical practice is warranted to verify the
retrospective analyses of this assay in clinical trials and ensure its cost-effectiveness for
routine use in this population.
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Chapter 4

4

Cost-effectiveness of a 21-gene recurrence score
assay versus Canadian clinical practice in postmenopausal women with early-stage estrogen or
progesterone-receptor-positive, axillary lymph-node
positive breast cancer

4.1 Abstract
A 21-gene recurrence score (RS) assay provides a method of guiding treatment decisions
in women with early-stage breast cancer (ESBC). I investigated the cost-effectiveness of
using the RS-assay versus current clinical practice (CCP) in post-menopausal women
with estrogen- or progesterone-receptor-positive (ER+ or PR+), one to three positive
axillary lymph-node (1-3 LN+), ESBC from the perspective of the Canadian public
healthcare system. I developed a decision analytic model to project the lifetime clinical
and economic consequences of ESBC. I assumed that the RS-assay would classify
patients among risk levels (low, intermediate and high) and corresponding adjuvant
treatment regimens. The model was parameterized using 7 year follow up data from the
Manitoba Cancer Registry, cost data from Manitoba Health administrative databases and
secondary sources. Costs are presented in 2012 Canadian dollars, and future costs and
benefits were discounted at 5%. In the base case, the RS-assay compared to CCP led to
an increase of 0.08 QALY and an increase in cost of $36.2 CAD per person, resulting in
an incremental cost effectiveness ratio (ICER) of $464/QALY gained. The ICER was
most sensitive to the proportion of women classified to intermediate risk by the RS-assay
who received adjuvant chemotherapy, and absolute risk of relapse among patients
receiving RS-assay. The RS-assay is likely to be cost effective in the Canadian healthcare
system. Field evaluations of the assay in this patient population will help reduce
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uncertainty in clinical guidelines for intermediate-range RS-assay values and specific
disease outcomes by RS-assay which are important drivers of ICER.

4.2 Introduction
Postmenopausal women with early stage estrogen or progesterone-receptor-positive,
axillary lymph-node positive breast cancer (ER+ or PR+ LN+ ESBC) are routinely
treated with chemotherapy in addition to endocrine therapy [176]. Recent data in Canada
and other jurisdictions have shown that these women, particularly those with favorable
histopathologic features (one to three positive axillary lymph nodes (1-3 LN+)), do not
benefit equally from chemotherapy [22, 177]. Further analyses have suggested that some
of these women may not gain benefit from adding chemotherapy to endocrine therapy
[177], [20]. These findings have highlighted the need for accurate prognostic tools to
identify women with ER+ or PR+ 1-3 LN+ ESBC who could be spared chemotherapy.
A 21-gene recurrence score assay (Oncotype DX) has been developed that provides a
“tumor signature” reflecting tumor biology and risk of relapse [11, 18-20]. This assay
uses a proprietary algorithm to combine tumor expressions of 21 genes into a single score
called the recurrence score (RS) which ranges from 1 to 100 [18]. Women with a low RS
(< 18) may need adjuvant endocrine therapy only, while those with a high RS (≥ 31) may
require the addition of chemotherapy to endocrine therapy [11, 19]. Women with an
intermediate risk (18 – 30) do not appear to obtain a large benefit from chemotherapy.
However, the uncertainty in the estimate cannot exclude a clinically important benefit
[11, 20, 25].
The prognostic value of the assay has been well documented for women with early-stage
estrogen or progesterone-receptor-positive, axillary lymph-node negative breast cancer
(ER+ or PR+ LN- ESBC) [11, 18-19]. There is increasing evidence that the recently
developed RS-assay can also identify women with ER+ or PR+ LN+ breast cancer
considered for adjuvant chemotherapy who will not benefit from this treatment [20, 120,
178-179]. The most comprehensive analysis of the RS-assay in women with ER+ or PR+
LN+ breast cancer was provided by a retrospective analysis of the phase III Southwest
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Oncology Group (SWOG)-8814, INT-0100 trial. The RS-assay was found to predict
disease free survival and overall survival in tamoxifen-treated post-menopausal women
with LN+, providing the first evidence of prognostic utility of the assay in a LN+
population receiving tamoxifen alone. In this study, it was shown that a low recurrence
score by the assay may define a group of post-menopausal women with LN+ who do not
appear to benefit from adjuvant chemotherapy [20]. A retrospective analysis of the
“Arimidex, Tamoxifen, Alone or in Combination” trial (ATAC) validated the prognostic
ability of the RS-assay in post-menopausal women with LN+ breast cancer treated with
endocrine therapy (anastrozole or tamoxifen). Specifically, the study defined a group of
ER+, 1-3 LN+ breast cancer patients with a low recurrence score who had less than 10 %
risk of distant recurrences [179]. Consistent results by both retrospective analyses [20,
179] provided “Level I” data according to the revised Levels of Evidence (LOE) scale
proposed by Simon el al [180] to determine the clinical utility of a tumor marker. Other
studies have also shown similar prognostic utility of the RS-assay in LN+ disease setting
[120, 178].
There are several economic evaluations suggesting that the RS-assay might be cost
effective in the ER+ or PR+ LN- ESBC population in Canada [132-134, 181], and other
countries [127-131]. However, findings in the LN- disease setting cannot be extrapolated
to LN+ disease setting due to differences in both clinical and economic outcomes. Three
economic analyses have examined the cost effectiveness of the RS-assay in both LN-and
LN+ settings [130, 133-134, 182]. These analyses suggested that the assay is costeffective for LN+ women in Canada[133], USA [182], and Japan [130]. However, none
of these analyses focused on the low risk subset of LN+ disease setting (1-3 LN+) for
whom the RS-assay is likely to be used in real world clinical practice, and suffered from
other limitations as indicated elsewhere [181]. Additionally, findings from studies in
USA and Japan cannot be extrapolated to the Canadian context because of possible
variations in clinical practice and different approaches to pricing and reimbursement.
I sought to investigate the cost effectiveness of the RS-assay compared to current clinical
practice (CCP) of adjuvant chemotherapy in women with ER+ or PR+ 1-3 LN+ ESBC
from the perspective of the Canadian healthcare system.
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4.3 Methods
4.3.1

Overview of Model-Structure

I developed a decision analytic model (Figure 3) to estimate the life time health and
economic consequences of different adjuvant treatment-guiding strategies for
postmenopausal women diagnosed with ER+ or PR+ 1-3 LN+ ESBC. The decision node
(Figure 3 a) of this model is a decision whether to use the RS-assay or the CCP strategy.
For the RS-assay-based strategy, a patient’s risk classification (low, intermediate and
high) was determined and followed by treatments decision (endocrine therapy plus
chemotherapy versus endocrine therapy alone) according to the RS-assay. For the CCP
based-strategy, all women are considered high risk and candidates for adjuvant
chemotherapy [176]. CCP classifies patients to different treatment regimens after taking
into consideration potential comorbidities. In either strategy, patients treated with
endocrine therapy alone followed Markov model “E” (Figure 3b) and those treated with
chemotherapy plus endocrine followed Markov model “C” (Figure 3c). Model “C”
differs from model “E” in that it has an additional health state to account for possible
chemotherapy-related serious adverse effects (CSAE) during chemotherapy.
Model “E” simulated monthly transitions among the following five distinct health
states: (1) remission; (2) loco-regional recurrence (LR); (3) distant recurrence (DR); (4)
second primary breast cancer (SPBC); (5) death. Model “C” simulated monthly
transitions among the following six distinct health states: (1) remission with no CSAE;
(2) remission with CSAE; (3) LR; (4) DR; (5) SPBC; (6) death.
The analysis was conducted from the Canadian health care payer’s perspective. I
used TreeAge Software to produce and evaluate the decision analytic model, using a half
cycle correction [136]. A discount rate of 5% per annum was applied to costs and quality
adjusted life years (QALYs) following recommendations by the Canadian Agency for
Drugs and Technologies in Health [111]. Parameter values are summarized in Table 1.
Collection and analysis of registry and administrative data used for this study was
approved by the University of Manitoba’s Health Research Ethics Board.

53

Figure 3. Decision model for early stage breast cancer.
a RS-assay versus CCP-guided therapy.
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c Schematic representation of the Markov model structure “C”.
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Patients entering Markov model “E” start the model and remain in the remission state unless they relapse (LR, DR, SPBC
or Death). Patients entering Markov model “C” start the model in the remission state with no CSAE. Within the first cycle
patients may develop CSAE. These patients will make a transition to the remission state with CSAE. During the first cycle,
patients also may transition to DR, LR, SPBC and Dead states. After the first cycle, patients may remain in the two
remission states unless they relapse in to LR, DR, SPBC or Dead. In both Markov models, patients who developed LR,
remain in the LR state or make transition to DR or Dead states. Patients who developed DR remain in the DR state or make
transition to Dead state. Patients who developed SPBC remain in the SPBC state or make transition to LR, DR or Dead
states. The cycle length was 1 month. Abbreviations: CCP= Canadian clinical practice; LR= loco-regional recurrence;
DR= distant recurrence; SPBC= second primary breast cancer; CSAE= chemotherapy-related serious adverse effects; RS=
recurrence score.
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4.3.2

Identification of a Study Cohort

The Manitoba Cancer Registry (MCR) and Manitoba administrative databases held by
Manitoba Health, including the Hospital Discharge Database, Physician Claims Database
and the Drug Program Information Network (DPIN), served as the main data source for
this analysis. I used the MCR to identify all post-menopausal women (defined as age ≥50
years) diagnosed with ER+ or PR+ 1-3 LN+ ESBC (stage II/III) during the period
January 1, 2000 − December 31, 2002. Seven-year follow-up information from the time
of diagnosis was available for each patient. This included breast cancer complications
(LR, DR and SPBC) and treatments (surgery, radiation therapy, endocrine therapy and
chemotherapy). I linked the study population identified using the MCR with
administrative data held by Manitoba Health including the Hospital Discharge Database,
the Physician Claims Database and the Drug Program Information Network.
Identification of our study cohort from MCR and linking with Manitoba administrative
databases are described in detail elsewhere [177].

4.3.3

Risk Distribution and Transition Probabilities

For the CCP model, women were classified as belonging to two treatment groups based
on observed adjuvant chemotherapy administration status (Table 6). I conducted survival
analyses within each group, using 7 years of follow up data from the Manitoba Cancer
Registry and Kaplan-Meier estimates, and used this information to estimate all transition
probabilities in the CCP Markov models.
For the RS-assay model, I used retrospective analysis of the phase III SWOG-8814, INT0100 trial to calculate the risk distribution and monthly transition probabilities to LR,
DR, SPBC and Death over 10 years within each risk level (Table 6) [20]. I obtained
Kaplan Meier (KM) survival curves for DFS and death events stratified by risk level from
SWOG investigators. These survival curves were restricted to women with 1-3 LN+ for
the purpose of our patient population of interest. DFS was defined as survival free from
recurrence (LR or DR), SPBC, and death from any cause. I estimated the distribution of
DFS events across LR, DR, SPBC and death categories based on a corresponding
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distribution of DFS events across these categories derived from our studied ER+/ PR+ 13 LN+ ESBC cohort.
Ongoing research is yet to clarify what the best adjuvant treatment approach is for
women with intermediate-range RS-assay values. For LN+ patients, the only available
data were provided recently by a survey of physician practice showing an overall
reduction in recommendation for chemotherapy in LN+ patients following the RS-assay
[183]. However, the study did not provide the actual usage of chemotherapy in
intermediate risk women with LN+ disease. In the base case I assumed that 50% of
women in the intermediate risk group would receive adjuvant chemotherapy as suggested
elsewhere [181]. I varied this assumption in sensitivity analysis.
Outcomes after first relapse (LR, DR, SPBC and Death) may not be affected by the
primary adjuvant therapy received [150]. Thus, only the probabilities of first relapse
differed between the CCP and RS-assay based strategy. I assumed the observed average
monthly transition probability from remission to first relapse during the last observed
year of follow up in the studied population and the SWOG-8814, INT-0100 trial to be
constant over the extrapolated time period. I used the age-adjusted female-specific life
tables for Manitoba to adjust the probabilities from remission to death in order to account
for the incremental mortality risk over the extrapolated time [151].
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Table 6. Base case parameter estimates and sources.

Base
case
value

Range tested
in sensitivity
analyses€

Distribution
used in
PSA†

Data Source

32.2
28.1
39.8

27.6 – 37.1
23.7 – 32.9
34.9 – 44.9

Dirichlet
Dirichlet
Dirichlet

[20]
[20]
[20]

64
100

56.3 – 70.1
90 – 100

Beta
Beta

RS-Assay – Medium Risk

50

0 – 100

Beta

RS-Assay – Low Risk
CSAE (%)
Health-State Utilities‡

0
6

0 – 10
0 – 14.6

Beta
Beta

MCR and PC
[20]
[131, 148-149,
152]
[20]
MCR and HA

Variables
Risk classification when using CCP (%)
High risk
Risk classification when using RS- assay (%)
High risk
Intermediate risk
Low risk
Chemotherapy administration by risk group (%)
CCP – High risk
RS-Assay – High risk

Remission state
Remission on chemotherapy regimen with
minor or no toxicityβ
Remission on chemotherapy regimen with
major toxicityβ
Remission after chemotherapy regimen
Remission on hormonal therapy
Remission after hormonal therapy

Duration

100

0.783

6 months

-20%

Beta

[153-155]

0.577

6 months

-20%

Beta

[153-155]

0.808
0.816
0.824

Lifetime
60 months
Lifetime

-20%
-10% – +10%
-10% – +10%

Beta
Beta
Beta

LR/SPBC, under treatment

0.577

12 month

-10% – +10%

Beta

LR/SPBC, after treatment

0.700

Lifetime

-10% – +10%

Beta

Distant recurrence
Death state
Cost associated with remission (per month), $
First year after diagnosis with ESBC
Cost of surgerya
Cost of radiation therapyb
Cost of endocrine therapyc
Tamoxifen
Aromatase Inhibitors
Sequential aromatase→ tamoxifen
Cost of chemotherapyd

0.412
0

Lifetime

-10% – +10%

Beta

[155-156]
[153-155]
[153-155]
[150, 153-155,
184]
[150, 153-155,
184]
[150, 153-155]

3529
3276

One time
One time

3187 – 3871
2628 – 4086

LogNormal
LogNormal

PC, HA and CL
PC and CL

12.4
156
72

12 months
12 months
12 months

11.6 – 13.2
120 – 193
62 – 81

LogNormal
LogNormal
LogNormal

DPIN
DPIN
DPIN

LogNormal

CL

LogNormal

PC

Nursing, overhead and administration costs
Related physician costs
Chemotherapy regimen options
CMF
CA
TAC
Weighted average cost of chemotherapy regimense
First three months on chemotherapy
Next
Cost of CSAE f

317.62
27

During
chemotherapy
During
chemotherapy

24 – 30

823
1151

5 months
3 months

LogNormal

MCR

LogNormal

MCR

2800

5 months

LogNormal

MCR

1099
432

3months
2months
During
chemotherapy

LogNormal
LogNormal

MCR
MCR

1376 – 2168

LogNormal

PC, HA and CL

54 – 62
96 – 103

LogNormal
LogNormal

PC
PC

1,750

g

Surveillance
Endocrine alone treated-patient
Chemo + endocrine treated-patient

56
99

12 months
12 months
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After first year of diagnosis with ESBC
Cost of endocrine therapyc
Tamoxifen
12.4
48 months
11.6 – 13.2
LogNormal
DPIN
Aromatase Inhibitors
156
48 months
120 – 193
LogNormal
DPIN
Sequential aromatase→ tamoxifen
72
48 months
62 – 81
LogNormal
DPIN
Surveillancef
34
Lifetime
30– 39
LogNormal
PC
Endocrine alone treated-patient
Chemo + endocrine treated-patient
44
Lifetime
39 – 51
LogNormal
PC
Cost associated with LR (per month), $
First year after LR
Surgerya
1768
One time
1092 –3313
LogNormal
PC, HA and CL
1725
One time
1353 – 2181
LogNormal
PC, HA and CL
Radiation therapyb
Cost of endocrine therapyc
Tamoxifen
12.4
12 months
11.6 – 13.2
LogNormal
DPIN
Aromatase Inhibitors
156
12 months
120 – 193
LogNormal
DPIN
LogNormal
DPIN
Sequential aromatase→ tamoxifen
72
12 months
62 – 81
Chemotherapyd
438
5 months
278 – 970
LogNormal
PC and CL
110
12 months
41 – 261
LogNormal
PC
Surveillance during first yearg
After first year of LR
Cost of endocrine therapyc
Tamoxifen
12.4
48 months
11.6 – 13.2
LogNormal
DPIN
LogNormal
DPIN
Aromatase Inhibitors
156
48 months
120 – 193
Sequential aromatase→ tamoxifen
72
48 months
62 – 81
LogNormal
DPIN
40
Lifetime
30 – 87
LogNormal
PC
Surveillance after first year of LRg
Cost associated with SPBC (per month), $
First year after SP
1494
One time
923 – 2800
LogNormal
PC, HA and CL
Surgerya
Radiation therapyb
1092
One time
286 – 510
LogNormal
PC, HA and CL
Endocrine therapy (options)c
Tamoxifen
12.4
12 months
11.6 – 13.2
LogNormal
DPIN
Aromatase Inhibitors
156
12 months
120 – 193
LogNormal
DPIN
LogNormal
DPIN
Sequential aromatase→ tamoxifen
72
12 months
62 – 81
553
5 months
353 – 1235
LogNormal
PC and CL
Chemotherapyd
Surveillance during first yearg
124
12 months
60 – 278
LogNormal
PC
After first year of SPBC
Cost of endocrine therapyc
Tamoxifen
12.4
48 months
11.6 – 13.2
LogNormal
DPIN
Aromatase Inhibitors
156
48 months
120 – 193
LogNormal
DPIN
LogNormal
DPIN
Sequential aromatase→ tamoxifen
72
48 months
62 – 81
Surveillance after first year from SPBCg
55
Lifetime
35 – 95
LogNormal
PC
Cost associated with DR (per month), $
First year after DR
Hospitalizations cost
2993
12 months
216 – 6273
LogNormal
HA and CL
Physicians cost
314
12 months
166 – 462
LogNormal
PC
Drugs cost
85
12 months
37 – 113
LogNormal
DPIN
After first year of DR
Hospitalizations cost
840
Lifetime
309 – 1361
LogNormal
HA and CL
Physicians cost
257
Lifetime
153 – 362
LogNormal
PC
Drugs cost
56
Lifetime
6 – 108
LogNormal
DPIN
€ Ranges used in sensitivity analyses were based on the same data sources as baseline values. Ranges used in sensitivity analyses of parameters
estimated from the Manitoba Cancer Registry and administrative databases in Manitoba were based on observed confidence intervals. Ranges used
in sensitivity analysis of parameters estimated from the retrospective analysis of the phase III SWOG-8814, INT-0100 trial were based on
confidence intervals reported in this study. Ranges used in sensitivity analysis of utility estimates were based on arbitrary ranges reported in utility
sources.
† Beta distribution was used for other probability parameter estimates not included in this table.
‡ Utility estimates were based on visual analog scales (VAS). The baseline utility for post-menopausal women aged 50 to 80 was 0.824, based on
representative values for the US population [155]. I derived utilities for each state by multiplying this baseline utility value by utility estimates for
patients with breast cancer [150, 153, 156, 184] in the US, consistent with methodology as described by Fryback [154].
β I used a disutility of 10% for a patient receiving chemotherapy with minor toxicity, a disutility of 30% for a patient receiving chemotherapy with
major toxicity, and a disutility of 0% for patients receiving chemotherapy with no toxicity [153]. The disutility for major toxicity was applied to
women experienced a major toxicity in our study population (i.e., 6% of our study population). A disutility average of 5% (i.e., average of 10% and
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0% disutility estimates with minor toxicity and no toxicity respectively) was applied to all other women with minor or no toxicity.
a Cost of breast cancer surgery: I used the Hospital Discharge Database and the Physician Claims Database to estimate the mean cost of
hospitalization due to any breast cancer surgery (including one day hospitalization and using the ICD-9-Cprocedure codes for a hospital abstract)
within one year after diagnosis with ESBC, LR and SPBC.
b Cost of radiation therapy: Cost of radiation therapy included cost of radiation therapy–related physician claims in addition to administrative cost. I
used the Physician Claims Database to estimate the mean cost of radiation therapy–related physician claims (using the tariff code for a medical
claim) within one year after diagnosis with ESBC, LR and SPBC. Administrative costs were derived from the cost list for Manitoba health services.
c Cost of endocrine therapy: I used the Drug Program Information Network (DPIN) to estimate the mean cost of tamoxifen and aromatase inhibitors
(using the drug identification number (DIN) for a drug claim) within the time periods, between diagnosis with ESBC and before any relapse,
diagnosis with LR and before any relapse, and diagnosis with SPBC and before any relapse.
d Cost of chemotherapy: Nursing, overhead and administration costs were derived from the cost list for Manitoba health Services. I used the
Physician Claims Database to estimate the mean cost of chemotherapy–related physician claims costs (using thetariff code for a medical claim)
within one year after diagnosis with ESBC, LR and SPBC. Chemotherapy regimens costs were estimated based on the market prices as of May
2012.
e Weighted average cost of adjuvant chemotherapy regimens: I calculated the average cost of adjuvant chemotherapy regimens weighted to the
observed proportion use of anthracyclines and taxane reported somewhere else [177]. Weighted average cost of adjuvant chemotherapy regimens =
proportion of women received non-anthracyclines containing adjuvant chemotherapy × cost of CMF + proportion of women received anthracyclines
containing adjuvant chemotherapy (no added taxanes) × cost of AC + proportion of women received anthracyclines and taxanes containing adjuvant
chemotherapy × cost of TAC.
f Cost of CSAE: I used the Hospital Discharge Database and the Physician Claims Database to estimate the mean cost associate with
hospitalizations due to any of the eight diagnoses which were considered CSAE among women who developed CSAE.
g Cost of surveillance: I defined the cost of breast cancer surveillance as the incremental cost of health care utilization (medical claims) after
diagnosis with ESBC versus the time before diagnosis. I used the Physician Claims Database to collect medical claims for all women studied, within
3 years before and 7 years after diagnosis wit ESBC. I estimated the mean cost of medical claims within 3 years before diagnosis in order to reflect
the usual cost of health care utilization. I calculated the incremental mean cost of health care utilization during the period from diagnosis with ESBC
and before any relapse (excluding cost of claims related to surgery, radiation therapy, chemotherapy, CSAE) stratified by the time from diagnoses
(first year versus after). Similarly, I calculated the incremental mean cost of health care utilization after LR and SPBC.
PSA= probabilistic sensitivity analysis; MCR= Manitoba Cancer Registry: PC= physician claims; HA= Hospital abstracts; CL= cost list for
Manitoba health services; DPIN=Drug Program Information Network records; ESBC= early stage breast cancer; LR, loco-regional recurrence; DR=
distant recurrence; SPBC=second primary breast cancer; CMF= 6 cycles of cyclophosphamide, methotrexate, 5-fluorouracil; AC= 4 cycles of
doxorubicin, cyclophosphamide; FAC= 6 cycles of fluorouracil, doxorubicin, cyclophosphamide; TAC= 6 cycles of docetaxel, doxorubicin,
cyclophosphamide; CCP= current clinical practice; CSAE= chemotherapy-related serious adverse effects; RS= recurrence score.
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4.3.4

Adjuvant Chemotherapy Regimens and Adjuvant
chemotherapy-related Serious Adverse Effects

Data on specific chemotherapy agents are not collected by the MCR and Manitoba
administrative databases. I was able to ascertain a non-anthracycline-, anthracycline- or
taxane-containing chemotherapy regimen by linking with the Physician Claims Database
and identifying the specific tariff index for services relating to those agents as described
elsewhere [177]. I considered patients who received non-anthracycline-containing
adjuvant chemotherapy regimens received 6 cycles of cyclophosphamide, methotrexate,
5-fluorouracil (CMF); that patients who received anthracycline-containing adjuvant
chemotherapy regimens with no added taxanes received four cycles of doxorubicin
(Adriamycin), cyclophosphamide (AC); and that patients who received anthracycline and
taxane-containing adjuvant chemotherapy regimens received 6 cycles of docetaxel,
doxorubicin, cyclophosphamide (TAC). In Canada, these three adjuvant chemotherapy
regimens were available for women with ER+ or PR+ 1-3 LN+ ESBC during the time
period of 2000-2003 [176-177]”. In the base case analysis I used the weighted average
cost of CMF, AC and TAC. In sensitivity analysis I considered each of these regimens
separately as the standard adjuvant chemotherapy regimen for postmenopausal women
with ER+ or PR+ 1-3 LN+ ESBC. I linked the study population with the Hospital
Discharge Database in order to estimate the rate of adjuvant chemotherapy-related
serious adverse effects (CSAE) using the method developed by Charlson et al. excluding
cancer diagnoses [165] as described in detail elsewhere [181].

4.3.5

Cost and Utility Values

According to the Annual Report Card of the Cancer Advocacy Coalition of Canada, the
RS-assay will cost $4,000 CAD per patient including all Canadian system expenses
[124]. I estimated all relevant treatment costs for ESBC including the cost of surgery,
radiation therapy, chemotherapy, and endocrine therapy, and the cost of CSAE
management and surveillance over 7 years following diagnosis. All these treatments are
publically funded in Manitoba and recorded in Manitoba health databases. I used these
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cost estimates to derive the cost per unit time in each Markov state (Table 6). All costs
are expressed in 2012 CAD using the bank of Canada inflation calculator [185].
I assumed a baseline utility of 0.824 for postmenopausal women in order to account for
background morbidity [155]. I multiplied the baseline utility by utility estimates for
women with breast cancer [150, 153-154, 156, 184] to calculate utilities across health
states (Table 6). I examined the impact of potential long term side effects of adjuvant
chemotherapy on health related-quality of life [166] by performing sensitivity analysis on
utility values following adjuvant chemotherapy.

4.3.6

Analysis

The cost-effectiveness analysis was conducted according to recommendations by the
Canadian Agency for Drugs and Technologies in Health [111]. Results are presented in
the form of cost-effectiveness ratio (ICER) which provides a measure of average cost per
additional unit of health benefit. Outcomes for health effects are measured in QALYs
(i.e., life-years weighted by utility estimates to produce QALYs). Cost outcomes were
measured as the mean cost per patient. To characterize uncertainty in the output
measures, I conducted one and two-way deterministic sensitivity analyses on parameters
of interests. In addition, I conducted probabilistic sensitivity analysis using Monte Carlo
simulation with 1000 iterations. Each iteration consisted of a random draw from an
appropriate distribution for all model inputs to produce a distribution of model outputs.
I conducted value-of-information analysis [112] to determine the expected monetary
value of perfect information about the RS-assay in the Canadian setting. In particular, I
set up our baseline model to express RS-assay related parameters (i.e., risk classification
by RS-assay, adjuvant chemotherapy assignment following RS-assay and probabilities of
first relapse following RS-assay) as probability distributions (i.e., reflecting uncertainty
of the RS-impact in the Canadian setting) on the basis of retrospective analysis of the
phase III SWOG-8814, INT-0100 trial [20] and the entire model is set up as a
probabilistic model. Using simulation techniques (i.e., making random draws of the
probabilistic model), the level of uncertainty in the model is assessed. Using a
willingness to pay threshold of $100,000 per QALY gained [69], the opportunity cost
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associated with the choice of RS-assay as the optimal strategy for guiding adjuvant
therapy is calculated and presented as a total of expected value of perfect information
(EVPI) about the RS-assay per patient. Using the size of ER+ or PR+ 1-3 LN+ ESBC
population, one can calculate the EVPI about the RS-assay for the entire target population
that could potentially benefit from more research on the predictive value of the RS-assay
in the Canadian setting. In particular, the EVPI may provide decision makers with
valuable information about the use of novel funding models such as conditional funding
alongside a field evaluation [113].

4.4 Results
Patient, tumor, treatment and event characteristics of the study cohort are reported
elsewhere [177]. There were 161 post-menopausal women diagnosed with ER+ or PR+
1-3 LN+ ESBC during the period from January 1, 2000 to December 31, 2002 in
Manitoba. The median patient age was 61 years (range 50–89 years). The majority of
women (95%) received surgery (mastectomy or lumpectomy) for their primary breast
cancer. Radiation therapy, endocrine therapy (tamoxifen or aromatase inhibitors) and
chemotherapy were administered in 60%, 89% and 64% of women respectively. The RSassay led to an increase of 0.08 QALY per person and an increase in cost of $36.2 CAD
per person, resulting in an incremental cost effectiveness ratio (ICER) of $464 per QALY
gained (Table 7).
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Table 7. Baseline outcomes†.
Strategy

Effectiveness

Incremental
Effectiveness

Cost

Incremental
Cost

ICER

CCP
15.73 QALY
$49093.0
$464 per QALY
0.08 QALY
$36.2
gained
RS-assay
15.81 QALY
$49129.2
† Due to rounding, numbers may not balance
CCP= current clinical practice; RS=recurrence score; ICER= incremental cost effectiveness ratio; QALY= quality
adjusted life year.
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4.5 Sensitivity Analyses
In the base case I compared the RS assay versus CCP when the weighted average cost of
CMF, AC and TAC was used. I considered each of CMF, AC, and TAC regimens
separately as the standard adjuvant chemotherapy regimen for women with ER+ or PR+
1-3 LN+ ESBC in sensitivity analysis. The RS-assay had an ICER of $4,150 per QALY
gained with CMF, $152 per QALY gained with AC, and was cost saving with TAC. The
utility during chemotherapy and the rates and costs of CSAE did not substantially
influence our baseline results (Table 8).
I performed threshold analyses on the proportion of chemotherapy-treated women in the
intermediate risk group by the RS-assay, risk of relapse in the RS-assay model, and
several other parameters (Table 8). The RS-assay generated negative cost and effect (the
RS-assay led to decrease in cost and effect) when fewer than 36% of women in the RSassay intermediate risk group received adjuvant chemotherapy. If the absolute risk of
relapse in the RS-assay model increased by approximately 2.6% then RS-assay would be
dominated by CCP.
I performed a probabilistic sensitivity analysis (Figure 4a) comparing the RS-assay
versus CCP. I simultaneously varied all parameters (probabilities, utilities and costs)
using appropriate distributions (Table 6). Using a willingness to pay threshold of
$100,000 per QALY gained, I found that the RS-assay was the preferred strategy in 72%
of simulations (Figure 4b).
I also performed a value-of-information analysis in which I estimated the expected
value of removing all statistical uncertainty of the RS-assay related parameters [112].
This type of analysis is necessary to estimate, in monetary values, the societal impact of
future research that can evaluate the RS-assay in real life Canadian clinical practice.
Using a willingness to pay threshold of $100,000 per QALY gained, the opportunity cost
associated with the choice of RS-assay as the optimal strategy for guiding adjuvant
therapy resulted in a total of EVPI of $4,200 per post-menopausal woman with ER+ or
PR+ 1-3 LN+ ESBC. Subsequently, I estimated the expected value for the entire ER+ or
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PR+ 1-3 LN+ ESBC population that could potentially benefit from more research on the
predictive value of the RS-assay in the Canadian setting. In Manitoba, there were
approximately 80 women diagnosed with ER+ or PR+ 1-3 LN+ ESBC. Based on the size
of Manitoba relative to the rest of Canada, I anticipate a total of approximately 2216
postmenopausal women diagnosed with ER+ or PR+ 1-3 LN+ ESBC who would be
eligible for the 21 gene assay in Canada. The resulting population EVPI was more than
$9.3 CAD million per year.
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Table 8. Summary of important one-and two way sensitivity analysesa.
Interpretation of the incremental impact of the RS-assay compared to CCP

Variable (range tested)
Chemotherapy treated women in
intermediate risk group by the RS-assay
(0% to 100%)
Change in absolute risk of relapsebin the
RS-assay model(-10% to +10%)
Lower limit cost of
recurrencec and SPBR
Change in utility
Baseline cost of
of recurrencec
recurrencec and SPBR
and SPBR
Upper limit cost of
(-10% to +10%)
recurrencec and SPBR

Negative
cost and
effect
0% to 36%

Cost savings
37% to 47%

ICER in the
range
0 to < 20,000
$/QALY gained

ICER in the range
≥ 20,000 to ≤100,000
$/QALY gained

ICER in the range
> 100,000 $/QALY
gained

Dominated

<+2.2%

≥ +2.2% to ≤ 2.3%

> +2.3% to ≤+2.6%

> +2.6%

≤ -6%

> -6%

48% to 100%

-10% to +10%
-10% to+10%

Change in utility during adjuvant
chemotherapy
-20% to 0%
(-20% to 0%)
Change in utility following adjuvant
≤ +1.5%
+1.6% to <+2 %
≥+2% to ≤+2.2%
> +2.2%
chemotherapy (-10% to +10%)
Chemotherapy-related serious adverse
(0% to 14.6%)
effects (0% to 14.6%)
Cost of chemotherapy-related serious
($1376 to $2168)
adverse effects ($1376 to $2168 )
CCP= current clinical practice; SPBR= second primary breast cancer; RS=recurrence score;
a
Valuesin the table show how the incremental impact of the RS-assay compared to CCP changes, over 6 significant ranges, depending on the values of certain
key parameters. For example, if between 37%-47% of women identified as intermediate risk by the RS-assay were to receive chemotherapy, then the RS-assay
would be cost saving relative to CCP; if this proportion is 48% or greater, then the RS-assay has an ICER between 0 and $20,000 / QALY gained.
b
Relapse includes loco-regional recurrence, distant recurrence, SPBR and death due to any cause.
c
Recurrence includes loco-regional and distant recurrences.
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Figure 4. Incremental cost-effectiveness scatterplot and acceptability curve of recurrence
score (RS)-assay versus CCP-guided therapy. Sampling distributions and summary
estimates of cost, efficacy, and variance were based on 1000 replicates.
a
Incremental Cost Effectiveness Scatter plot of RS-assay versus CCP

Incremental cost
(thousands of dollars)

1.5
1
0.5
0
-1

-0.5

0

0.5

1

-0.5
-1
-1.5

Incremental effectiveness (QALY)
b

Probability of being cost effective

Cost-Effectiveness Acceptability Curve of RS-assay versus CCP
80%
70%
60%
50%
40%
30%
20%
10%
0%
0

1
2
3
4
5
Willingness to pay ($/QALY) gained'000s

CCP

RS-assay
CCP= current clinical practice.
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4.6 Discussion
I developed a decision-analytic model to evaluate the cost effectiveness of the RS-assay
versus CCP in post-menopausal women with ER+ or PR+ 1-3 LN+ ESBC. In the base
case, I estimated that the RS-assay has an ICER of $464 per QALY gained. Our ICER
estimate is significantly lower than $20,000 per QALY gained, a level which has been
suggested in Canada to define “strong evidence in support of adoption” [69] and below
levels of recently adopted cancer treatments (e.g., [169-170]).
Previous cost-effectiveness analyses of the RS-assay in LN+ disease population have
several limitations and may not be applicable in the Canadian context. Two studies did
not incorporate results from the retrospective analysis of the phase III SWOG-8814, INT0100 trial [20], which established the relationship between the RS-assay and the benefit
from using chemotherapy in the LN+ disease setting. One of these analyses [130] was
based on data from the National Surgical Adjuvant Breast and Bowel Project (NSABP)
B20 trial for LN- disease [11] with relevant adjustments for baseline relapse risk and
reported a favourable ICER of$5,685 USD per QALY gained in a subset analysis
involving LN+ disease. The second analysis [182] found the RS-assay to be cost saving
in LN+ disease setting due to predicted reductions of chemotherapy utilization after RS
testing, but did not employ specific disease outcomes according to RS risk groups. One
recent study has incorporated specific disease outcomes from the retrospective analysis of
SWOG 8814trial. However, modeling the current experience of LN+ disease (i.e.,
without the RS-assay) with regard to survival in this study was not based on Canadian
data and did not reflect real world clinical practice, and the model did not incorporate all
breast cancer complications such as second primary breast cancer [132-133]. More
importantly, the study did not focus on the low risk subset of LN+ disease setting (1-3
LN+) for whom the RS-assay is likely to be used in real life clinical practice and instead
considered women with all levels of nodal involvement to be eligible for the RS-assay.
There is no robust Canadian or international data yet to suggest that women with
extensive nodal involvement (i.e., ≥ 4LN+) would not benefit from a treatment strategy
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including chemotherapy [186]. Thus, the RS-assay may have no clinical utility for these
women.
Our finding is consistent with earlier analyses of the RS-assay in the LN- disease setting.
The ICER of the RS-assay in post-menopausal women with ER+ or PR+ 1-3 LN+ ESBC
was within ICER ranges of the assay in women with LN- disease in Canada. For instance,
in a recent analysis the RS-assay compared to CCP in LN- patient population generates
cost-savings in pre-menopausal women and has an ICER of $60,000 per QALY gained in
post-menopausal women (2012) [181]. Other ICER estimates for LN- disease in Canada
are at $9,591 (2012) [133] and $63,064 (2010) [132] per QALY gained.
As of January 2013, the test is not publically funded for women with 1-3 LN+ disease in
any Canadian province and these women are not currently eligible for inclusion in
ongoing field evaluations of the RS-assay [186]. However, unlike the use of the RS-assay
in LN+ disease, the use of the assay in LN- disease with reimbursement mechanisms is
increasing across Canada. It became available for women with LN- disease in several
provinces in a limited fashion or within context of a field evaluation [124-126]. Our value
of information analysis in ER+ or PR+ 1-3 LN+ ESBC setting demonstrated that future
research that can characterize the role of the RS-assay in real world Canadian practice
may have a large societal impact, when willingness to pay levels of recently accepted
cancer treatments are considered. Taken together with recent Canadian findings [177] on
adjuvant chemotherapy efficacy in this particular patient population, this suggest that
future field evaluations of the assay to establish its impact on Canadian practice should
include postmenopausal women with 1-3 LN+ disease in addition to women with LNdisease.
The results of the retrospective analysis of SWOG 8814trial [20]are the first and only
findings that indicate the prognostic utility of the RS-assay in LN+ disease population
receiving tamoxifen alone. Our model was sensitive to the disease specific outcomes by
the RS-assay derived from this analysis particularly for women included with 1-3 LN+
disease. Additionally, our analysis demonstrated that the ability of the RS-assay to guide
treatment decisions in the intermediate risk group will likely be important in determining
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whether the RS-assay will be a cost-effective use of resources. An ongoing prospective
randomized trial (SWOG S-1007) [26] will determine the effect of chemotherapy in
patients with 1-3 LN+ disease who do not have high RS by RS-assay. This trial will
provide new evidence regarding the clinical utility of the RS-assay in this particular
disease setting and further assess the predictive value of the assay in women falling in the
intermediate risk group. However, findings from this trial will not be available for 5 years
whereas an adoption decision will need to be made prior to having the results of this trial.
I used the Manitoba Cancer Registry and Manitoba Health administrative databases to
model current real-world Canadian clinical practice. This approach may increase model
complexity but it has the advantage of providing us with longitudinal patient, clinical and
treatment data on a large number of patients and for a long follow up time (7 years). This
allows us to estimate significant clinical outcomes (e.g., local recurrence, regional
recurrence, second primary, chemotherapy-related serious adverse effects) that are
otherwise hard to model using secondary data sources. This approach to decision
modeling and cost-effectiveness analyses have been considered helpful in identifying
data needs and quantifying uncertainty about a new medical intervention in the “real
world” Canadian setting [187]. A more thorough discussion of the use of registry and
administrative data to conduct cost-effectiveness analyses in the Canadian setting has
been discussed elsewhere [188].
This study has limitations. First, the clinical utility of the RS- assay in women with 1-3
LN+ disease was based on retrospective analysis of the phase III SWOG-8814, INT-0100
trial conducted in the United States [20]. Thus, disease outcomes by the RS-assay may
not necessarily reflect the experience of the ER+/PR+ 1-3 LN+ ESBC identified in
Manitoba due to potential differences in patient and tumor characteristics and treatments.
In regard to this shortcoming, reports from prospective analyses of the assay in real-world
Canadian clinical practice are awaited to update our model and verify our results. Second,
clinical guidelines are still awaited for women with intermediate-range RS-assay values
[26]. Third, outcomes and costs of therapies given in the 2000-2002 population do not
necessary reflect the possible benefits and costs of other newer types of adjuvant
therapies (e.g., third generation anthracycline-taxane regimens) or dosing schedules used
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in current practice so analysis with such data would be more applicable to the current
practice landscape. Finally, although clinical practice patterns employed in the selected
time period in Manitoba have shown to reflect practices in other jurisdictions in Canada
[88, 174-175], management of women with ER+/PR+ 1-3 LN+ ESBC and its associated
costs may be still different.

4.7 Conclusion
The RS-assay compared to CCP is likely to be cost-effective in postmenopausal women
with ER+ or PR+ 1-3 LN+ ESBC. Current use of the assay with public reimbursement
mechanisms should be extended to include cases with 1-3 LN+ disease in addition to LNcases. Field evaluations of the assay to establish its impact on CCP in women with
ER+/PR+1-3 LN+ ESBC should be initiated to ensure its clinical utility and costeffectiveness in this patient population.
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Chapter 5

5

Cost-effectiveness of using a microarray-based gene
expression test to aid in identifying primary tumor
versus Canadian clinical practice in patients with cancer
of unknown primary

5.1 Abstract
A microarray-based gene expression test called the tissue of origin (TOO) test provides a
method to predict the likely primary tumor site in cancer of unknown primary (CUP) by
testing the biopsy specimen of the metastatic tumor. I sought to investigate the costeffectiveness of using the TOO test to help identify primary tumor versus current clinical
practice (CCP) in patients with CUP from the perspective of the Canadian public
healthcare system. I developed a decision analytic model to project the lifetime clinical
and economic consequences of CUP. I assumed that CUP patients present with occult
primary tumor sites. Within each occult primary tumor setting, the TOO test may either
lead to tumor specimen classification or indeterminate results. I assumed that TOO tumor
classification would be interpreted after careful clinicopathologic and radiologic
assessment and this may lead to correctly or incorrectly diagnose primary tumor or
primary tumor stays undiagnosed, and correspondently guide patient management. The
model was parameterized using 2 year follow up data from the Manitoba Cancer
Registry, cost data from Manitoba Health administrative databases and secondary
sources. Costs are presented in 2013 Canadian dollars (CAD), and future costs and
benefits were discounted at 5%. In the base case, the TOO-based strategy compared to
CCP led to an increase of 0.28 life year (LY) and 0.24 quality-adjusted life year (QALY)
and an increase in cost of $10,807 CAD per person, resulting in an incremental cost
effectiveness ratio (ICER) of $37,774 per LY gained and $44,151 per QALY gained. The
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ICER was most sensitive to the accuracy of the TOO test, diagnostic results following
TOO tumor classification and patient survival response following correct primary
diagnosis. The TOO test is likely to be cost effective in the Canadian healthcare system
and should be considered for adoption in patients with CUP. However, field evaluations
of the test to establish its impact on Canadian management of CUP and resulting survival
outcomes are warranted for further investigation.

5.2 Introduction
The Canadian Cancer Society estimates that approximately 186,400 new cases of cancer
will occur in Canada in 2013 [189]. Of these new cases, up to 4% are of metastatic cancer
types not readily classified in the course of the initial diagnostic work up which includes
careful exanimation of clinical history, full physical examination (including head and
neck, breast, pelvic and rectal examination) and chest radiograph [190]. International and
Canadian clinical guidelines recommend a further diagnostic work-up for these metastatic
patients including blood and biochemistry survey, urinalysis, fecal occult blood test,
imaging procedures, cytogenetic studies, electron microscopy and immunohistochemical
(IHC) analysis [190]. Additional evaluation and endoscopies are recommended to be
sign-or symptom-guided [190]. In the past decade, improvements in the number and
accuracy of IHC stains have enabled to make highly accurate tissue-of-origin diagnosis in
many of these metastatic patients. However, the current success rate of the diagnostic
work-up, even after exhaustive clinical and pathologic investigation, varies from 20% to
25% [39, 41]. Consequently, over 3% of all incident cancer cases are metastatic cancer of
unknown primary origin (CUP) recorded annually in tumor registries across Canada,
accounting for approximately 5000-7000 cases of CUP annually. The majority of these
CUP cases were proven by autopsy series to have small clinically undetectable (i.e.,
occult) primary tumor sites [191].
In the absence of a specific tumor diagnosis, there has been no consensus of defined
treatment guidelines. Several broad-spectrum empiric chemotherapeutic regimens (not
specific for the nature of cancer) based on combination regimens of platinum or taxane
have generally been used [192-193]. However, patients have a poor prognosis with a
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median survival of 8-12 months from diagnosis and 1-year survival probabilities ranging
from 15% to 35% [41].
The ability to identify a primary tumor site has been and continues to be the most
important goal in the clinical management of any patient with metastatic cancer. When
tumor origins are known, patient outcomes and even survival may improve [194-195].
This is because oncologists have better information on which to base treatment strategies
and can allow patients to benefit from the increasing availability of specific and more
effective therapy regimens, which may include specific chemotherapy or therapy
designed to target biologic characteristics of specific malignancies.
Prediction of the likely primary tumor site by testing the biopsy specimen of the
metastatic tumor is improving through the use of gene expression profiling techniques
[196-197]. To date, several gene expression-based tests have demonstrated the potential
value of this approach in identifying the primary site. However, only one test called “the
Tissue of Origin (TOO)” test is clinically viable option and fulfill criteria for successful
translation [54-55] according to publically available evidence [48, 59]. The TOO test
(Response Genetics, Inc., Los Angeles, CA) is a microarray-based gene expression test
for identifying a tumor’s primary site using formalin-fixed paraffin-embedded (FFPE)
specimens. The test compares the RNA profile of a tumor FFPE specimen to established
RNA profiles of 15 known tissues. The test measures the degree of similarity between the
expression patterns of the tumor and those of a panel of 15 different tissue types. The
TOO test result is presented as 15 separate similarity scores (SS) (which are interpreted
as probabilities), one for each tissue type on the panel. The highest SS indicates the most
likely tissue of origin. An SS of 30 or less indicates indeterminate results. When a
specimen is found to include less than 60% of tumor content and more than 20% necrosis
the TOO test results are considered indeterminate regardless of SS.
The test was validated on independent 462 formalin-fixed paraffin-embedded (FFPE)
specimens derived from metastatic or poorly differentiated tumor specimens of known
primary cancers and showed 89.3% accuracy in identifying tumor’s primary site [59].
The analysis included at least 25 specimens per tissue type and considered indeterminate
results. In 2012, the test was reviewed and cleared by the Food and Drug Administration
and has been clinically offered in the United States [60]. The TOO test results are
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intended for use in the context of the patient’s clinicopathologic and radiologic history by
a qualified oncologist and pathologist [198-200]. For instance, initial or additional
clinical history, IHC analyses, and computed tomography (CT) scan images should be
correlated and consistent with TOO tumor classification when suggesting a potential
primary tumor site.
The impact of the test on health and economic outcomes, if introduced into general
clinical practice for CUP patients, has not been determined. The TOO test has official list
price of $4,400 CAD per patient. As of January 2014, the test is not publically funded in
any Canadian province and clinical management of CUP patients has not been influenced
by TOO testing. Developing recommendations for Canadian clinical practice regarding
the use of TOO test in CUP requires a comprehensive health economic evaluation of this
approach in the Canadian setting [69]. I sought to evaluate the cost-effectiveness of using
the TOO test to help diagnose the primary tumor and guide treatment decisions compared
to current clinical practice (CCP) in patients diagnosed with CUP from the perspective of
the Canadian health care system.

5.3 Methods
5.3.1

Model Overview

I developed a decision analytic model (Figure 5) to estimate the lifetime clinical and
economic consequences of different clinical management strategies for patients
diagnosed with CUP. The model begins with a decision to use the TOO test or to
continue with CCP (Figure 5a). In the CCP-based strategy (Figure 5b), I classified CUP
patients according to their occult primary tumor sites. Within each occult primary tumor
site, I assumed that patients are treated according to existing clinical guidelines when
primary tumor site stays undiagnosed. In the TOO-based strategy (Figure 5c), I classified
CUP patients according to their occult primary tumor sites. Within each occult primary
tumor site I assumed that the TOO test results would either classify the tumor specimen
to one of the 15 tissue types included in the test panel or lead to indeterminate results
(i.e., when SS is ≤ 30, encounter unique specimens harboring less than 60% tumor
content, or actual tissue of origin for a given tumor specimen is not covered by the 15
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tissue types included in the test panel) (Figure 5c). When TOO test results classify the
tumor specimen, these results would either be correct or incorrect. I assumed that TOO
tumor classification would be interpreted after careful clinicopathologic and radiologic
assessment (CRA). When clinicopathologic correlation can be established with TOO test
results (i.e., correct or incorrect), I assumed that TOO tumor classification would be
considered and may lead to correct or incorrect cancer diagnosis and guide treatment
decisions (Figure 5c). When clinicopathologic correlation cannot be established with the
TOO test results (i.e., correct or incorrect), I assumed that TOO tumor classification
would not be considered and primary tumor may stay undiagnosed (Figure 5c).
CUP patients whose primary tumor stays undiagnosed in both strategies or those who
have their primary tumor incorrectly diagnosed in the TOO-based strategy entered model
“A” (Figure 5d). CUP patients who have their primary tumor correctly diagnosed in the
TOO-based strategy entered model “B” (Figure 5e). Model “A” differs from model “B”
in that it has an additional health state to account for possible detection of an eventual
primary tumor later during the course of the disease (latent primary).
Model “A” simulated monthly transitions among the following five distinct health states:
(1) Initial diagnosis of metastasis (IDM); (2) diagnosis of latent primary (LP); (3)
diagnosis of second primary (SP); (4) palliative care (PC); (5) death. Model “B”
simulated monthly transitions among the following four distinct health states: (1) IDM;
(2) SP; (3) PC; (4) death.
The analysis was conducted from the Canadian health care payer’s perspective. I applied
a discount rate of 5% per annum to costs, life years (LY) and quality adjusted life years
(QALYs) following recommendations by the Canadian agency for Drugs and
Technologies in Health [111]. I used a lifetime horizon and half cycle correction [136]. I
used TreeAge Software to populate and evaluate the decision analytic model [136]. Data
collection and analysis using Manitoba administrative databases (including the Manitoba
Cancer Registry, the Hospital Discharge Database, the Physician Claims Database and
the Drug Program Information Network) were approved by the University of Manitoba
Health Research Ethics Board and Western University Health Research Ethics Board.
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Figure 5. Decision model for CUP.
a TOO testversus CCP-guided clinical management.

TOO-based strategy

Technology
Adoption
Decision

CCP-based strategy

b CCP-guided clinical management.
Bladder
Breast
Colorectal
Gastric
Germ Cell
Kidney
CCP-based
strategy

Hepatocellular
Non-Small Cell Lung
Non-Hodgkin’s Lymphoma
Melanoma
Ovarian
Pancreas
Prostate
Sarcoma
Thyroid
Others

Primary Stays Undiagnosed
Markov “A”
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c TOO-guided clinical management.
Bladder
Breast
Colorectal
Gastric
Germ Cell
Kidney
TOO-based
strategy

Hepatocellular
Non-Small Cell Lung
Non-Hodgkin’s Lymphoma
Melanoma
Ovarian
Pancreas
Prostate
Sarcoma
Thyroid
Others

Correct Diagnosis of
Primary after CRA
Markov “B”

Correct
Classification
Primary Stays
Undiagnosed after CRA
Classification of Tumour
Specimen by TOO test
Primary Stays
Undiagnosed after CRA
Incorrect
Classification
Incorrect Diagnosis of
Primary after CRA

Indeterminate Results by TOO test
and Primary Stays Undiagnosed

Markov “A”

Markov “A”

Markov “A”

Markov “A”
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d Schematic representation of the Markov model structure “A”.

LP
SP

IDM
PC

Dead

e Schematic representation of the Markov model structure “B”.

SP

IDM
PC

Dead

Decision node

Chance node

Transition

Patients entering Markov model “A” start the model and remain in the IDM state unless they develop LP or SP, start PC, or die.
Patients who developed LP remain in the LP state or make transition to SP, PC, or Dead states. Patients entering Markov model
“B” start the model and remain in the IDM state unless they develop SP, start PC, or die. In both Markov models, patients who
developed SP, remain in the SP state or make transition to PC or Dead states. Patients who started PC remain in the PC state or
make transition to Dead state. The cycle length was 1 month. Abbreviations: CCP= Canadian clinical practice; TOO= Tissue of
Origin; CRA= clinicopathologic and radiologic assessment; IDM= initial diagnosis of metastasis; LP= diagnosis of latent
primary; SP= diagnosis of second primary; PC= palliative care.
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5.3.2

Identification of a Study Cohort

The MCR is a provincial database that contains the records for more than 99.5% of all
cases of cancer in Manitoba and is a comprehensive cancer registry [137]. Information on
cancer staging, based on the American Joint Commission on Cancer (Version 5), has
been routinely collected for all cancer sites since January 1995 [138]. The MCR also
collects information on demographics, clinical tumor characteristics, disease progression,
SP cancer, death, and cancer treatments. I used the MCR to identify a study cohort
consisting of all metastatic cancer patients (defined as diagnosed initially with stage IV or
diagnosed with distant metastasis within 4 months of initial diagnosis) during the period
from January 1, 2002 to December 31, 2011. I limited the study cohort to those who are
Manitoba residents, 18 to 90 years old and with no history of malignancy at initial
diagnosis. Since the end of the accrual period is 2011, a minimum of two-year follow-up
information from the time of initial diagnosis was available for each patient. This
included diagnosis of SP, cancer treatments (e.g., surgical procedures, therapeutic
radiology procedures, endocrine therapy, chemotherapy, biological therapy, and palliative
care) and death. I linked all patients with administrative data held by Manitoba Health
including the Hospital Discharge Database, the Physician Claims Database and the Drug
Program Information Network. To protect confidentiality, the linkage was performed
with a scrambled health number using anonymatized versions of these databases.
For each patient in our study cohort, I used the MCR to establish the initial diagnosis
status of primary tumor site. I used initial tumor specific-files (i.e., historical data)
available on cancer patients in the registry and search for codes representing the
anatomical sites (i.e., using the International Classification of Diseases for Oncology
(ICD-O) topography diagnosis codes). I linked all patients with their tumor specificupdated files available in the MCR (i.e., linkage performed via both tumor ID and
scrambled health number). I then identified those who have their initial primary
anatomical site status changed to different site at least 6 months after their initial
diagnosis. This 6 month window is considered necessary and reasonable to ensure that
the diagnoses of the later primary anatomical sites were not the results of extension in the
initial diagnostic work up [10]. I considered these patients to have a LP tumor site
subsequently detected during their life or at autopsy.
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I stratified our study cohort to three patient groups; (1) metastatic patients diagnosed
initially with CUP: defined as those who were initially diagnosed with CUP (i.e., using
the ICD-O topography diagnosis code c80.9) and either had their LP detected or
undetected later during their life or at autopsy; (2) metastatic patients diagnosed initially
with their true primary site: defined as those who were initially diagnosed with known
primary and had no change detected with their primary diagnosis later during their life or
at autopsy); (3) metastatic patients diagnosed initially with their incorrect primary site:
defined as those who were initially diagnosed with a given known primary and had a LP
detected later during their life or at autopsy). For each patient group, I ascertained PC
from both the MCR and by linking with the Physician Claims Database and using the
specific tariff index of PC as provided by physicians.

5.3.3

Distributions and Transition Probabilities

I defined CCP for CUP according to the observed administration of treatments and
survival outcomes in metastatic patients diagnosed initially with CUP (i.e., patient group
“1”). I conducted survival analyses using Kaplan-Meier estimates using 2 years of follow
up data from the MCR, and used this information to estimate all transition probabilities in
the CCP Markov model “A”.
For the TOO model I estimated the distribution of occult primary tumor sites among CUP
patients (Table 9) based on the observed distribution of LPs among the subset of patients
initially diagnosed with CUP who had their LP tumor site subsequently detected during
their life or at autopsy. For each occult primary tumor site in the TOO model, I extracted
the distribution of patients across TOO test results (i.e., classification of tumor specimen
(correct and incorrect) or indeterminate results) and across diagnostic results after CRA
(correct diagnosis of primary, incorrect diagnosis of primary, and undiagnosed primary)
from a recent validation analysis [59] and clinical verification of the TOO test
performance [198] (Table 9).
I assumed that CUP patients whose primary is correctly diagnosed would have survival
outcomes similar to those of observed metastatic patients diagnosed initially with their
true primary site [191]. Thus, I conducted survival analyses using Kaplan-Meier
estimates for metastatic patients diagnosed initially with their true primary site (i.e.,
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patient group “2”). I stratified this analysis by primary tumor site, using 2 years of follow
up data from the MCR, and used this information to estimate all transition probabilities in
the TOO Markov models following the chance nodes when the primary is correctly
diagnosed. I assumed that CUP patients whose primary stays undiagnosed or is
incorrectly diagnosed would have survival outcomes similar to those of observed
metastatic patients diagnosed initially with CUP(i.e., patient group “1”) [191].
To extrapolate transition probabilities for lifetime, I assumed the observed average
monthly transition probabilities during the last observed year of follow up in the studied
population to be constant over the extrapolated time period. However, projected survival
beyond 2 years was low in our metastatic patient population.
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Table 9. Base case probabilities and sources.

Variables
Distribution of occult primary tumor sites among CUP patients
(%)
Bladder
Breast
Colorectal
Gastric
Testicular germ cell
Kidney
Hepatocellular
Non-small cell lung
Non-Hodgkin’s lymphoma
Melanoma
Ovarian
Pancreas
Prostate
Sarcoma
Thyroid
Others
Distribution of patients according to classification provided by
the TOO within each occult primary tumor site (%)
Bladder
Classification of tumor specimen
Incorrect classification
Correct classification
Indeterminate results
Breast
Classification of tumor specimen
Correct classification
Incorrect classification
Indeterminate results
Colorectal
Classification of tumor specimen
Correct classification
Incorrect classification
Indeterminate results
Gastric
Classification of tumor specimen
Correct classification
Incorrect classification
Indeterminate results
Hepatocellular
Classification of tumor specimen
Correct classification
Incorrect classification
Indeterminate results
Germ cell
Classification of tumor specimen
Correct classification
Incorrect classification
Indeterminate results
Kidney
Classification of tumor specimen
Correct classification
Incorrect classification

Base
case
Value

Duration

Range tested
in sensitivity
analyses

Distribution
used in PSA†

Data Source
MCR

0
1.5
8.9
3.8
0.5
3.5
1
27
5.3
4.56
9.6
8.9
1.5
1.27
0.76
21.91

Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
[59]

93
79.3
20.7
7

90 – 100
60.3 – 92
8 – 39.7
0 – 10

93
96.5
3.5
7

90 – 100
87.9 – 99.6
0.4 – 12.1
0 – 10

93
91.7
8.3
0

90 – 100
77.5 – 98.2
1.8 – 22.5
0 –10

93
72
28
7

90 – 100
50.6 – 87.9
12.1 – 49.4
0 –10

93
96
4
7

90 – 100
79.6 – 99.9
0.1 – 20.4
0 –10

93
84
16
7

90 – 100
63.9 – 95.5
4.5 – 36.1
0 –10

93
89.3
10.7

90 – 100
71.8 – 97.7
0.3 – 28.2

Beta
Beta

[198]
[59]
[59]
[198]

Beta
Beta

[198]
[59]
[59]
[198]

Beta
Beta

[198]
[59]
[59]
[198]

Beta
Beta

[198]
[59]
[59]
[198]

Beta
Beta

[198]
[59]
[59]
[198]

Beta
Beta

[198]
[59]
[59]
[198]

Beta

[198]
[59]
[59]
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Indeterminate results

7

0 –10

Beta

[198]

Melanoma
Classification of tumor specimen
93
90 – 100
[198]
Correct classification
84
63.9 – 95.5
[59]
Incorrect classification
16
0.5 – 36.1
Beta
[59]
Indeterminate results
7
0 –10
Beta
[198]
Non-Hodgkin’s lymphoma
Classification of tumor specimen
93
90 – 100
[198]
Correct classification
89.7
72.6 – 97.8
[59]
Incorrect classification
10.3
2.2 – 27.4
Beta
[59]
Indeterminate results
7
0 –10
Beta
[198]
Non-small cell lung
Classification of tumor specimen
93
90 – 100
[198]
Correct classification
85.2
66.3 – 95.8
[59]
Incorrect classification
14.8
4.2 – 33.7
Beta
[59]
Indeterminate results
7
0 –10
Beta
[198]
Ovarian
Classification of tumor specimen
93
90 – 100
[198]
Correct classification
88.9
75.9 – 96.3
[59]
Incorrect classification
11.1
3.7 – 24.1
Beta
[59]
Indeterminate results
7
0 –10
Beta
[198]
Pancreas
Classification of tumor specimen
93
90 – 100
[198]
Correct classification
85.7
67.3 – 96
[59]
Incorrect classification
14.3
4 – 32.7
Beta
[59]
Indeterminate results
7
0 – 10
Beta
[198]
Prostate
Classification of tumor specimen
93
90 – 100
[198]
Correct classification
96
79.6 – 99.9
[59]
Incorrect classification
4
0.1 – 20.4
Beta
[59]
Indeterminate results
7
0 –10
Beta
[198]
Sarcoma
Classification of tumor specimen
93
90 – 100
[198]
Correct classification
88.9
70.8 – 97.6
[59]
Incorrect classification
11.1
2.4 – 29.2
Beta
[59]
Indeterminate results
7
0 –10
Beta
[198]
Thyroid
Classification of tumor specimen
93
90 – 100
[198]
Correct classification
90.3
74.2 – 98
[59]
Incorrect classification
9.7
2 – 25.8
Beta
[59]
Indeterminate results
7
0 –10
Beta
[198]
Others
Classification of tumor specimen
67
[198]
Correct classification
0
[59]
Incorrect classification
100
[59]
Indeterminate results
33
0–50
Beta
[198]
Distribution of patients across diagnostic results after CRA
within each occult primary tumor site (%)
Correct classification
Correct diagnosis of primary
100
90 – 100
Beta
[198]
Undiagnosed primary
0
0 – 10
[198]
Incorrect classification
Undiagnosed primary
100
90 – 100
Beta
[198]
Incorrect diagnosis
0
0 – 10
[198]
† Beta distribution was used for other probability parameter estimates not included in this table.
PSA= probabilistic sensitivity analysis; MCR= Manitoba Cancer Registry; CUP= Cancer of unknown primary; CRA= Clinicopathologic and
radiologic assessment.
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5.3.4

Costs

The cost of the TOO test, after all Canadian health system expenses are added, is
estimated at $4,400 CAD per patient. The management costs of metastatic cancer
including treatment costs (e.g., surgical procedures, radiation therapy, chemotherapy,
endocrine therapy, biological therapy, etc.), costs of follow up, costs of managing
treatment side effects, and cost of palliative care are all publicly funded in Manitoba and
recorded in the administrative databases held by Manitoba Health.
I used the Hospital Discharge Database to estimate the costs of inpatients and one day
procedure stays for our study cohort during their disease course following the initial
diagnosis. I used the Resource Intensity Weights [201-202] recorded for inpatient stays
and Day Procedure Group Weights [201-202] recorded for day procedure stays to reflect
the resources consumed during hospital contacts. I converted these weights into dollars
using a multiplier known as the Cost Per Weighted Case [201-202]. I used the Physician
Claims Database to estimate the cost of medical claims made by physicians (and other
health care providers) for insured services provided to our patient cohort during their
disease course following the initial diagnosis. In addition, I used the Drug Program
Information Network to estimate the cost of prescription claims made by our study cohort
during their disease course following the initial diagnosis.
I used the costs of hospital stays, medical claims and prescription claims for our study
cohort to estimate the cost per unit time in each Markov state (Table 10). I used the costs
collected for metastatic patients diagnosed initially with CUP (i.e., patient group “1”) to
estimate the cost per unit time in each state of Markov model following the chance nodes
when the primary stays undiagnosed in both the CCP and TOO-based strategy. I used the
costs collected for metastatic patients diagnosed initially with their true primary site (i.e.,
patient group “2” stratified by primary tumor site) to estimate the cost per unit time in
each state of TOO Markov models following the chance nodes when the primary is
correctly diagnosed. To account for costs associated with incorrect primary diagnosis in
the TOO-based strategy, I used the costs collected for metastatic patients diagnosed
initially with their incorrect primary site (i.e., patient group “3” stratified by primary
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tumor site) to estimate the cost per unit time in each “IDM” state of TOO Markov models
following the chance nodes when the primary is incorrectly diagnosed. I estimated cost
per unit time in other states of TOO Markov models following the chance nodes when the
primary is incorrectly diagnosed by using costs collected for metastatic patients
diagnosed initially with CUP (i.e., patient group “1” stratified by primary tumor site). All
costs are expressed in 2013 CAD.
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Table 10. Base case cost estimates and sources.

Variables
Cost associated with IDM (per month), $
Breast
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Colorectal
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Gastric
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Hepatocellular
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Kidney
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Melanoma
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost

Base
case
value

Duration

Distribution
used in PSA†

Data Source

983
257
73

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

490
131
89

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1273
533
73

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

730
284
89

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1425
398
46

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

1372
271
72

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

943
185
42

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

737
19
27

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1353
373
78

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

1019
224
93

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

508
290
78

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

748
164

Lifetime
Lifetime

Normal
Normal

HA
PC
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Cost of prescription claims
Non-Hodgkin’s lymphoma
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Non-small lung
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Ovarian
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Pancreas
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Prostate
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Sarcoma
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Germ cell
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
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Lifetime

Normal

DPIN

1620
346
123

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

1414
183
77

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

885
241
33

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

773
164
83

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

2618
392
69

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

1144
187
58

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1164
294
36

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

1345
241
171

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

961
243
60

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

771
119
64

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1451
552
127

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

470
119
176

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1109
606
129

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

89

After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Thyroid
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
CUP
First year after IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of IDM
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Cost associated with latent primary (per month), $
Patients initially diagnosed with CUP
First year after latent primary
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
After first year of latent primary
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Cost associated with palliative care (per month), $
Breast
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Colorectal
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Gastric
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Germ cell
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Kidney
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Hepatocellular
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Non-small lung
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost

903
139
26

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

854
417
39

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

484
89
45

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1145
210
51

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

541
90
100

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

970
191
88

12 months
12 months
12 months

Normal
Normal
Normal

HA
PC
DPIN

1724
150
88

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1214
236
98

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1226
204
77

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

790
149
56

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

594
10
0

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1277
259
184

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

544
142
27

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1116
175

Lifetime
Lifetime

Normal
Normal

HA
PC
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Cost of prescription claims
Non-Hodgkin’s lymphoma
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Melanoma
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Ovarian
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Pancreas
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Prostate
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Sarcoma
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Thyroid
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
CUP
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Cost associated with second primary (per month), $
Breast
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Colerectal
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Gastric
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Germ cell
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Kidney
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Non-small lung
Costs of inpatients and one day procedure stays
Physicians and other health care providers cost
Cost of prescription claims
Non-Hodgkin’s lymphoma
Costs of inpatients and one day procedure stays

67

Lifetime

Normal

DPIN

1012
242
268

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

853
241
94

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1182
158
71

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

819
144
55

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1358
200
88

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1215
197
112

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

463
102
49

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1233
184
83

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

527
265
42

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1283
511
128

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

464
102
11

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

711
1217
27

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

2518
285
164

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

1147
317
62

Lifetime
Lifetime
Lifetime

Normal
Normal
Normal

HA
PC
DPIN

876

Lifetime

Normal

HA
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Physicians and other health care providers cost
343
Lifetime
Normal
PC
Cost of prescription claims
138
Lifetime
Normal
DPIN
Melanoma
Costs of inpatients and one day procedure stays
1022
Lifetime
Normal
HA
Physicians and other health care providers cost
437
Lifetime
Normal
PC
Cost of prescription claims
166
Lifetime
Normal
DPIN
Ovarian
Costs of inpatients and one day procedure stays
600
Lifetime
Normal
HA
Physicians and other health care providers cost
202
Lifetime
Normal
PC
Cost of prescription claims
29
Lifetime
Normal
DPIN
Prostate
Costs of inpatients and one day procedure stays
1573
Lifetime
Normal
HA
Physicians and other health care providers cost
254
Lifetime
Normal
PC
Cost of prescription claims
83
Lifetime
Normal
DPIN
Sarcoma
Costs of inpatients and one day procedure stays
1246
Lifetime
Normal
HA
Physicians and other health care providers cost
517
Lifetime
Normal
PC
Cost of prescription claims
256
Lifetime
Normal
DPIN
Thyroid
Costs of inpatients and one day procedure stays
219
Lifetime
Normal
HA
Physicians and other health care providers cost
142
Lifetime
Normal
PC
Cost of prescription claims
48
Lifetime
Normal
DPIN
CUP
Costs of inpatients and one day procedure stays
910
Lifetime
Normal
HA
Physicians and other health care providers cost
307
Lifetime
Normal
PC
Cost of prescription claims
34
Lifetime
Normal
DPIN
Patients initially diagnosed with metastatic hepatocellular and pancreatic cancer did not have a second primary over the study
follow up period and thus costs associated with second primary are not included for hepatocellular and pancreas.
PSA= probabilistic sensitivity analysis; MCR= Manitoba Cancer Registry: PC= physician claims; HA= Hospital abstracts; DPIN=
Drug Program Information Network records; CUP= Cancer of unknown primary; IDM= Initial diagnosis of metastasis.
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5.3.5

Utilities

I undertook a systematic review of both primary research studies and economic models to
determine utilities for each health state in the Markov models (Table 11). I derived
different utility estimates for metastatic patients diagnosed initially with different known
primary sites. I assumed that CUP patients whose primary is correctly diagnosed may
have quality of life outcomes similar to those of metastatic patients diagnosed initially
with known primary site.
One recent study has focused on health related quality of life (HRQoL) among CUP
patients [203]. CUP patients were found to experience 13% more impaired HRQoL
compared with metastatic patients of known primary. In this study, I estimated the
weighted average utility of metastatic patients of known primary (i.e., weighted average
was based on the observed distribution of latent primary tumor sites in our CUP cohort
(Table 1)) at 0.64 (Table 11). When primary tumor site stays undiagnosed I estimated the
baseline utility at 0.56 after applying 13% reduction on the weighted average utility of
metastatic patients of known primary. When patients have the latent primary tumor site
subsequently detected during their life, I assumed that patients would experience quality
of life similar to those of metastatic patients diagnosed initially with corresponding
known primary site. I performed sensitivity analysis on the utility values to account for
uncertainty.
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Table 11. Utility values and sources.
Health states
Initial diagnosis of metastasis
Breast
Colorectal
Gastric
Hepatocellular
Kidney
Melanoma
Non-Hodgkin’s lymphoma
Non-small Lung
Ovarian
Pancreas
Prostate
Sarcoma

Utilityβ

Duration

0.715
0.730
0.729
0.650
0.760
0.580
0.805
0.530
0.740
0.600
0.740
0.690

LT
LT
LT
LT
LT
LT
LT
LT
LT
LT
LT
LT
LT

Testicular germ cell

0.776

Thyroid

0.780

Other primary tumor sites
Buccal cavity and pharynx
Esophagus
Small intestine
Gallbladder
Non-hepatocellular
Other digestive system
Other female genital system
Other male genital system
Small cell lung
Other lung
Ureter
Other urinary system
Multiple myeloma

0.670
0.670
0.730
0.650
0.650
0.730
0.740
0.740
0.530
0.530
0.760
0.760
0.805

Other endocrine
Weighted average utility of other
primary tumor sites^
Weighted average utility of metastatic
patients of known primary^
CUP*
Diagnosis of latent primary
Patient diagnosed with a given latent
primary

LT

Range tested
in sensitivity
analyses

Distribution
used in PSA

Data
Source

-20% – +20%
-20% – +20%
-20% – +20%
-20% – +20%
-20% – +20%
-20% – +20%
-20% – +20%
-20% – +20%
-20% – +20%
-20% – +20%
-20% – +20%
-20% – +20%

Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta

-20% – +20%

Beta

-20% – +20%

Beta

[60]
[204]
[205]
[206]
[207]
[208]
[209]
[210]
[211]
[212]
[213]
[214]
[215216]
[216217]
[218]
[218]
[204]
[206]
[206]
[204]
[211]
[213]
[210]
[210]
[207]
[207]
[209]
[216217]

0.800
0.649

LT

-20% – +20%

Beta

0.645

LT

-20% – +20%

Beta

0.560

LT

-20% – +20%

Beta

[203]

Corresponding utility of
patient initially diagnosed
LT
-20% – +20%
Beta
with metastasis of that
primary tumor
7% reduction of
corresponding utility of a
LT
-20% – +20%
Beta
[219]
Second primary tumor
given primary tumor site
0.4
LT
-20% – +20%
Beta
[220]
Palliative care
0
Death
β All utility estimates were based on EuroQOL five dimensions questionnaire (EQ-5D).
^ Weighted average was based on the observed distribution of latent primary tumor sites in our CUP cohort.
* Utility with CUP was derived after applying 13% reduction on the weighted average utility of latent primary tumor sites in CUP.
CUP= cancer of unknown primary; LT= lifetime.
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5.4 Results
5.4.1

Base-case scenario

There were 1,214 metastatic patients initially diagnosed in Manitoba from January 1,
2002 to December 31, 2011 with CUP and 405 (33%) of those patients had their latent
primary tumor site subsequently detected during their life or at autopsy. During the same
time period, there were 11,731 patients initially diagnosed with metastatic of known
primary in Manitoba and 2417 (20%) of those patients had their initial primary tumor
incorrectly identified and their true latent primary tumor detected later during life or at
autopsy. Patient, tumor, treatment and event characteristics of the study cohort are
summarized elsewhere [221].
Our model predicted 1.13 LY, 0.63 QALY and $17,802 CAD for CUP whereas when
primary tumor is properly identified our model outcomes ranged from 0.74 LY, 0.45
QALY, and $14,278 with hepatocellular to 4.35 LY, 3.37 QALY, $69,400 CAD with
testicular germ cell. A detailed summary for all Markov model outcomes is depicted in
Table 4. The TOO-based strategy led to an increase of 0.28 LY and 0.24 QALY per
person and an increase in cost of $10,807 CAD per person, resulting in an incremental
cost effectiveness ratio (ICER) of $37,774 per LY gained and $44,151per QALY gained
compared to CCP. Baseline outcomes are summarized in Table 12.
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Table 12. Baseline Markov model outcomes.
Effectiveness
LY
QALY
Breast
1.79
1.08
Colorectal
2.00
1.40
Gastric
1.09
0.73
Hepatocellular
0.74
0.45
Kidney
1.51
1.02
Melanoma
2.30
1.29
Non-Hodgkin’s lymphoma
3.05
2.41
Non-small Lung
1.08
0.53
Ovarian
1.86
1.31
Pancreas
0.75
0.43
Prostate
2.62
1.78
Sarcoma
1.88
1.22
Testicular germ cell
4.35
3.37
Thyroid
3.77
2.97
Unknown primary
1.13
0.63
LY= life year; QALY= quality adjusted life year.
Primary Tumor site

Cost
$30,874
$38,978
$26,985
$14,278
$34,157
$33,056
$68,662
$20,165
$50,000
$18,157
$40,942
$36,015
$69,400
$40,200
$17,802
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Table 13. Baseline study outcomes†.
Effectiveness

Incremental
Effectiveness

Strategy
LY

QALY

LY

QALY

Cost

Incremental
Cost

ICER
Per LY
gained

Per
QALY
gained

CCP
1.13
0.63
$17,802
0.28
0.24
$10,807
$37,774
$44,151
TOO test
1.42
0.87
$28,609
† Due to rounding, numbers may not balance
CCP= current clinical practice; TOO test= Tissue of Origin test; ICER= incremental cost effectiveness ratio; LY= life
year; QALY= quality adjusted life year.
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5.4.2

Sensitivity Analysis

In three-way sensitivity analysis I tested three groups of parameters: (1) Parameters
related to sensitivity of the TOO test across occult primary sites (i.e., correct or incorrect
classification of tumor specimen); (2) Parameters related to incorrect diagnostic results
following TOO specimen classification (i.e., when primary stays undiagnosed following
correct TOO classification of tumor specimen or when primary is incorrectly diagnosed
following incorrect TOO classification of tumor specimen); (3) Parameters related to
survival response following correct primary diagnosis (i.e., the transition probabilities
from IDM to PC, SP, or dead states in the TOO Markov models following the chance
nodes when the primary is correctly diagnosed). The TOO-based strategy generated an
ICER greater than $100,000 per QALY gained when the sensitivity of the TOO test
decreased by 50%, incorrect diagnostic results following TOO specimen classification
increased by 20% and survival response following correct primary diagnosis decreased
by 30% (Figure 6). Cost of the test and indeterminate TOO results across occult primary
sites did not substantially influence our baseline outcomes (Figure 7).
I performed a probabilistic sensitivity analysis (Figure 8a) comparing the TOO versus
CCP-based strategy. I simultaneously varied all parameters (probabilities, utilities and
costs) using appropriate distributions (Table 1, 2 and 3). Using a willingness to pay
threshold of $50,000 and $100,000 per QALY gained, I found that the TOO-based
strategy was the preferred strategy in 78.2% and 99.6% of simulations respectively
(Figure 8b).
I also performed a value-of-information analysis [112] to determine the expected
monetary value of perfect information about the impact of TOO test. This analysis is
necessary to estimate the societal impact of future research that can evaluate the TOO test
in real life Canadian clinical practice [112]. In particular, I set up our baseline model to
express all parameters related to the accuracy of the TOO test, diagnostic results
following TOO specimen classification, and survival response following correct primary
diagnosis as probability distributions (Table 9) and the entire model is set up as a
probabilistic model. I assessed the level of uncertainty in the model using simulation
techniques (i.e., making 1000 random draws of the probabilistic model). Using our
baseline ICER value of $44,151 per QALY gained as our willingness to pay, the
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opportunity cost associated with the choice of TOO-based strategy for guiding
management of CUP resulted in a total of expected value of perfect information (EVPI)
of $1,265.81 per patient diagnosed with CUP. Subsequently, I estimated the expected
value for the entire CUP population that could potentially benefit from more research on
the predictive value of the TOO test and its impact in the Canadian setting. In Manitoba,
there were 105 patients diagnosed with CUP in 2011. Based on the size of Manitoba
relative to the rest of Canada, I anticipate a total of approximately 2,923 patients annually
diagnosed with CUP who would be eligible for the TOO test in Canada. The resulting
population EVPI was 3.7million per year.

99

Figure 6. Sensitivity of the ICER to TOO accuracy1, incorrect diagnostic
results2following TOO classification and survival response3following correct primary
diagnosis.
a

b
10% Decrease of Baseline Survival Response Following
Correct Primary Diagnosis
100%

Percentage Increase of Incorrect Diagnostic
results following TOO Classification

Percentage Increase of Incorrect Diagnostic
results following TOO Classification

Baseline Survival Response Following Correct Primary
Diagnosis
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

Percentage Decrease of Baseline TOO
Accuracy

Percentage Decrease of Baseline TOO
Accuracy
d

Percentage Increase of Incorrect Diagnostic
results following TOO Classification

20% Decrease of Baseline Survival Response Following
Correct Primary Diagnosis
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

Percentage Decrease of Baseline TOO
Accuracy

30% Decrease of Baseline Survival Response Following
Correct Primary Diagnosis
100%

Percentage Increase of Incorrect Diagnostic
results following TOO Classification

c

90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

Percentage Decrease of Baseline TOO
Accuracy

100

ICER ≤ $50,000 per QALY gained
$50,000 < ICER ≤ $100,000 per QALY
$100,000 < ICER ≤ $150,000 per QALY
ICER > $150,000 per QALY
1
TOO test agreement with reference cancer diagnosis.
2
Incorrect diagnostic result was defined as when primary stays undiagnosed following correct TOO classification of tumor
specimen or when primary is incorrectly diagnosed following incorrect TOO classification of tumor specimen.
3
Survival response following correct primary diagnosis was defined as the transition probabilities from IDM to PC, SP, or dead
states in the TOO Markov models following the chance nodes when the primary is correctly diagnosed. Survival response
following correct diagnosis of hepatocellular, pancreas or non-small lung primary site was not included in sensitivity analyses as
these potential primary sites were found to have worse QALYs compared to overall CUP group (Table 4).
TOO test= Tissue of Origin test; ICER= incremental cost effectiveness ratio; QALY= quality adjusted life year; CUP= cancer of
unknown primary.
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Figure 7. Sensitivity of the ICER to cost of the TOO test and indeterminate TOO results.

ICERs ($/ QALY gained'000s)

50

40

30

20
$2,000 CAD per TOO test
$4,400 CAD per TOO test

10

$6,000 CAD per TOO test
0
0%

20%

40%

60%

80%

100%

Percentage Increase of Baseline Indeterminate TOO Results

TOO test= Tissue of Origin test; ICER= incremental cost effectiveness ratio; QALY= quality adjusted life
year.
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Figure 8. Incremental cost-effectiveness scatter plot and acceptability curve of TOO
versus CCP-based strategy. Sampling distributions and summary estimates of cost,
efficacy, and variance were based on 1000 replicates.
a
Incremental Cost Effectiveness Scatter plot of TOO versus CCP-based Strategy
Incremental cost (thousands of dollars)
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Incremental effectiveness (QALY)

b
Cost-Effectiveness Acceptability Curve of TOO versus CCP-based Strategy
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TOO test= Tissue of Origin test; CCP= current clinical practice.
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5.5 Discussion
I developed a decision-analytic model to evaluate the cost effectiveness of using the TOO
test to help diagnose primary tumors versus CCP in patients with CUP for whom no
anatomical primary tumor site was found after diagnostic work up undertaken according
to real life clinical practice in Manitoba. In the base case I found that the TOO-based
strategy has an ICER of $37,774 per LY gained and $44,151 per QALY gained.
In Canada, an ICER of $20,000 to $100,000 per QALY gained has been suggested as
representing “moderate evidence for adoption and appropriate utilization” [62, 72],
although there is no evidence that any Canadian decision-making body has formally
implemented these thresholds [168]. The ICER of the TOO-based strategy in patients
with CUP were within ranges of the microarray-based 21-gene expression test for breast
cancer that has recently been partly adopted in clinical practice in Canada [124-126]. The
21-gene assay for guiding adjuvant chemotherapy in early stage breast cancer has an
estimated ICER of up to $63,064 per QALY gained [132]. It became available in several
provinces in a limited fashion or within context of a field evaluation for hormone positive
and lymph node negative disease [124-126].
A recent cost-effectiveness analysis of the TOO test was reported among patients with
metastatic and poorly differentiated cancer of uncertain primaries (i.e. difficult-todiagnose primary) for whom the majority had primary tumor site diagnoses reported by
their physicians prior to TOO testing. The test was found to have an ICER of $46,858 per
QALY gained from a US third-party payer perspective. These results in uncertain cancers
cannot be extrapolated to the CUP setting since with CUP, despite extensive clinical and
pathological diagnostic evaluation, patients are left without a primary tumor site
diagnosis and as a result management and clinical outcomes are different. In our study I
examined the cost-effectiveness of incorporating TOO testing in patients diagnosed with
CUP for who all had no anatomically defined primary tumor site after the diagnostic
work up that was undertaken according to real life clinical practice in Manitoba.
Our sensitivity analysis (Figure 6a) demonstrated that the accuracy of the TOO test in
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classifying tumor specimens and diagnostic results following TOO tumor classification
are important drivers of the ICER. Both factors further impacted the ICER when
addingthe possibility that CUP patients may not respond as well as their counterparts
with metastatic of known primary cancers when occult primary is identified and treated
with current site-specific therapy (i.e. survival response following correct primary
diagnosis). For instance, when these three factors were negatively modified by
approximately 35% (Figure 6d) the ICER became well above ranges of a number of
cancer treatments recently approved for funding in Canada [169-170] and TOO-based
strategy may no longer deemed a cost effective use of resources.
Validation of the TOO test accuracy and clinical verification of resulting diagnostic
decisions in real-life CUP population remains a challenge since, by definition, the
primary tumor site is not found except rarely in the clinical course or commonly at
autopsy [10, 222]. Analyses of the TOO tests [59, 198] used in our study were conducted
in the United States in patients with known primary cancers. Genetic profiles of occult
cancers giving rise to CUP may differ from known primary cancers [222]. A more direct
study to evaluate the reliability of TOO test and its impact on diagnostic decision making
in CUP patients would be the correlation with an eventual primary tumor detected later
during the course of the disease (latent primary) or at autopsy. Such research approach
would be useful in the Canadian setting to address concerns over potential incorrect TOO
classification and resulting diagnostic decisions and to update our model and verify our
results.
Our value of information analysis demonstrated that future research that can characterize
the TOO test accuracy and resulting diagnoses and survival outcomes in CUP-real world
Canadian practice may have a large societal impact, when willingness to pay levels of
recently accepted cancer treatments are considered. Taken together with the lack of future
randomized trials of TOO testing in CUP population worldwide, this suggests that field
evaluations of the test to establish its impact on Canadian management of CUP and
resulting survival outcomes should be a priority.
Controversies have recently been raised on whether validation analyses of gene
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expression profiling assays may have been subject to tumor-biopsy specimen sampling
bias due to potential intratumoral heterogeneity [223]. Although analysts have run the
TOO test on duplicate samples from 44 cases (both clinical and research cases) and found
no differences in test outcome, I still remain uncertain as to whether these concordant
results may apply on the overall heterogeneous CUP population. Thus, future studies of
TOO testing in CUP population should further explore any potential impact of
intratumoral heterogeneity on its results using multiple tumor-biopsy samples.
Our analysis has limitations. First, there are limits to what can be ascertained through
administrative data. Even though the Manitoba Cancer Registry is a highly accurate
source of information about all cancer sites [137], errors in coding can result in incorrect
or unrecorded procedures. However, wherever possible I cross validated across
databases. For instance, information on palliative care can be found in both the Manitoba
Cancer Registry and the administrative databases held by Manitoba Health. Second,
outcomes and costs of therapies given in the 2002-2011 population do not necessary
reflect the possible benefits and costs of newer types of therapies or dosing schedules
used in current practice so analysis with such data would be more applicable to the
current practice landscape. Finally, although clinical practice patterns employed in the
selected time period in Manitoba have shown to reflect practices in other jurisdictions in
Canada [88, 174-175], management of patients with CUP and its associated costs could
be different.

5.6 Conclusion
I compared the use of TOO test to aide in primary tumor diagnosis versus CCP in patients
diagnosed with CUP. I found that the TOO-based strategy appears to provide good value
for money in this patient population. However, field evaluations of the test to establish its
accuracy and impact on diagnostic decisions and survival in the CUP setting should be
initiated in Canada to ensure its clinical utility and cost-effectiveness.
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Chapter 6

6

General discussion

6.1 Implications and recommendations
Creating evidence-based review of gene expression profiling technologies in clinical
oncology is becoming the primary challenge with the limited evidence base available
[224]. In particular, randomized controlled clinical trials and other high-quality evidence
is generally lacking for these technologies [225]. Moreover, Canadian data on patient and
clinician behavior based on these gene expression profiling results and the outcomes of
treatment decisions (i.e., effectiveness) may not be available [224]. I used Manitoba
administrative health databases and Manitoba Cancer Registry to parameterize decision
analytic models and predict the role of such emerging gene expression profiling
technologies in real world Canadian clinical oncology practice. This approach may have
increased model complexity but it has the advantage of providing us with longitudinal
patient, clinical and treatment data on a large number of patients and for a long follow up
time. This allowed us to estimate significant clinical outcomes (e.g. local recurrence,
regional recurrence, second primary, chemotherapy-related serious adverse effects, and
latent primary) that are otherwise hard to model using secondary data sources. This thesis
highlights the usefulness of the Canadian provincial administrative health databases and
disease registries as a source of information to inform health care decision making and
policy development. In Canada, administrative health and disease registry data have been
used for research purposes for decades. It was the establishment of the Manitoba Center
for Health Policy and Evaluation and the subsequent development of their population
health information system, POPULIS, which brought this data source into the spotlight.
Similar developments in other Canadian provinces since that time now offer health
researchers access to provincial administrative health data that can be linked across
services [82]. A more thorough discussion of the use of registry and administrative data
to conduct cost-effectiveness analyses in the Canadian setting has been discussed
elsewhere [188].
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It should be noted that emerging gene expression profiling technologies may not yet be
incorporated into the Canadian clinical practice and thus data about these technologies
may not be available from provincial administrative health databases or disease registries
in Canada. However, I have shown that analysts can still predict the role of these
technologies in real-world clinical practice when these databases are used to model
current real-world Canadian clinical practices (the current practice without these
technologies). Analysts can then apply available data about these technologies, which
might be derived from non-Canadian settings, on observed current clinical practice
models to examine how these data may alter the observed current clinical and economic
outcomes. Such decision modeling and cost-effectiveness analyses are helpful in
identifying data needs and quantifying uncertainty about these technologies in the real
world Canadian setting. For instance, value of information analysis (VOI) [112] can be
performed on these decision analytic models to inform policy options such as
conditionally funded field evaluation (CFFE) (i.e., coverage with evidence development)
[113].
Canadian provincial decision makers (e.g., the Ontario Health Technology Advisory
Committee (OHTAC)) are currently facing promising gene expression profiling (e.g.,
21-gene assay) that may improve patient safety and likely pose low risk of harm, but have
significant uncertainty associated with their clinical value [87, 226]. In such cases,
Canadian decision makers can recommend promising gene expression profiling
technologies for a conditionally funded field evaluations (CFFE) to be undertaken to
reduce uncertainty, and this could take the form of studies on quality, safety, efficacy,
effectiveness, and cost-effectiveness [113]. For instance, following a recommendation by
OHTAC, in Ontario the 21-gene assay became available for women with early stage
lymph node negative breast cancer within the context of field evaluation in December
2010 [227]. Organizations that provide the analysis to support provincial decision making
bodies (e.g. The Programs for Assessment of Technology in Health (PATH) Research
Institute) often use VOI analyses to determine the expected value of perfect information
(EVPI) about the technology. Comparing the EVPI with the cost of conducting a CFFE
can determine if it is worthwhile before actually conducting the evaluation [113]. If the
CFFE is determined not to be worthwhile (i.e., the cost of research is greater than the
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VOI gained from the research), this information is fed back to high level decision makers
and CFFE would not be considered [113]. On the other hand, if it is determined that the
CFFE is worthwhile, information on uncertainty from the economic model is further used
to refine CFFE study design. Hence, our VOI analyses in this thesis are likely relevant to
Canadian provincial decision makers who must make difficult decisions.
A close observation on the pharmaceutical industry may demonstrate that Canadian
decision makers will increasingly face this scenario with gene expression profiling and
other personalized medicine technologies in the near future and therefore use of health
administrative health data in decision analytic analyses should be a priority. The use of
administrative databases to model existing clinical practices would be the best approach
that analysts can take to predict the role of these technologies when compared with
existing clinical practices in real-world settings and to support health technology
assessment.
In addition, a current paradigm shift in pharmaceutical industry strongly suggests the
need to build an evidence base for clinical practice and policies in Canada using
provincial administrative health databases and disease registries. In this era, it becomes
reasonable to forgo randomized phase III clinical trials for drugs and medical
technologies that demonstrate substantial activity in early-phase clinical trials,
particularly for diseases with high unmet medical need [228]. In Canada, pharmaceutical
companies can get accelerated drug approval from the Therapeutic Product Directorate
(TPD) of Health Canada through the Notice of Compliance (NOC) policy which requires
less onerous evidentiary requirements and the review process itself is also significantly
accelerated [229]. In turn this will allow promising new drugs and technologies to
potentially be made widely available to patients sooner by avoiding the delays and cost
that seem inherent in completing phase III randomized clinical trials [228-230]. However,
forgoing randomized phase III clinical trials leads to less-definitive data regarding the
safety and efficacy of the new drug or technology [228]. Thus, conducting postmarketing studies to confirm clinical benefit becomes necessary. The Health Products
and Food Branch (HPFB) in Canada has, by virtue of the Food & Drugs Act and
regulations, nominal jurisdiction to ensure a manufacturer’s compliance through post-
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market surveillance [229]. When this occurs, drugs and medical technologies might be
released into the marketplace and their availability might deter patient participation in
post-marketing studies. Many pharmaceutical companies have failed or faced difficulties
in completing randomized or non-randomized confirmatory post-marketing studies due to
poor patient accrual [228, 231]. Decision analytic modeling techniques might then be
used to assess indirect evidence. In this regard, provincial health administrative databases
and disease registries in Canada may provide a great opportunity to assess the clinical
effectiveness of such drugs in real world Canadian clinical practice. It should be noted
that the development of specific billing codes for new drugs and emerging medical
technologies should be a priority in this era [232]. Such an effort will allow provincial
health administrative databases and disease registries to capture the use of these drugs or
technologies in the Canadian clinical practice [233]. In addition, analysts will be able to
conduct their decision modeling and cost-effectiveness analyses to assess effectiveness
and inform recommendations for appropriate clinical decision making. Such an effort will
contribute to building a high quality evidence base for examining these drugs and
technologies in real-world Canadian clinical practice. As well, efforts to maintain and
develop health administrative data standards across provinces, specifically to monitor
new drugs and emerging technologies through coding development would be helpful for
cross-regional comparisons. Provincial and territorial health ministries and disease
registries which hold and maintain administrative and registry data should share and
allow use of these data to academics and pharmaceutical industry. For instance, allowing
pharmaceutical companies to access Canadian health administrative databases and
disease registries will be helpful in conducting confirmatory post-marketing studies on
their drugs or medical technologies which might be a unique and effective tool for these
companies to assess the clinical and cost effectiveness of their products in real-world
settings [228, 230-231].
Given the promising role of health administrative data in this era, the process of
accessing and linking provincial health administrative databases and registries in Canada
should be accelerated and improved across all Canadian provinces. At the same time, it is
essential to ensure there is adequate privacy and security protection for personal health
information when data sets are linked. For instance, in Ontario, a collaborative agreement
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between the Institute for Clinical Evaluative Sciences (ICES) and Cancer Care Ontario
(CCO) has lead to the initiation of the Ontario Cancer Data Linkage Project (‘cd-link’).
This was an initiative of the Ontario Institute for Cancer Research and Cancer Care
Ontario Health Services Research Program to establish a data release program whereby
administrative datasets relevant to cancer health services research such as the Ontario
Cancer Registry and Ontario Health Insurance Plan claims are linked, de-identified and,
with the protections of a comprehensive Data Use Agreement, provided directly to
researchers. Such a provincial initiative is helping to speed research that contributes to
the effectiveness, quality, equity and efficiency of health care and health services
in Ontario. Similar initiatives in other Canadian provinces should be developed to offer
health researchers and other stakeholders’ access to provincial health administrative and
registry data that can be efficiently linked across services.
Currently, the emphasis in virtually all analyses evaluating gene expression profiling
technologies in clinical oncology is on the establishment of the value of each of these
profiling predictors over standard clinical predictors. However, as gene expression
profiling technologies mature and proliferate, an important question will be how they
compare to each other when these technologies target the same patient population, and
whether there is value in their combination or sequencing. In the therapeutic domain, this
has been called “comparative effectiveness” research. Such research has traditionally
been difficult to fund by government or by industry, because it may not hold out as much
therapeutic promise as new discoveries and industry understandably is not anxious to
fund head-to-head comparisons with competitive products. In the diagnostic domain,
such research is necessary to compare the effectiveness of combining different available
diagnostic technologies. For instance, Gould et al. developed a decision analytic model to
identify the most effective approaches to diagnose and manage solitary pulmonary
nodules [234]. Gould et al. compared 40 clinically plausible combinations of 5 available
diagnostic interventions, including computed tomography, positron emission tomography
with the glucose analogue 18-fluorodeoxyglucose (FDG-PET), transthoracic needle
biopsy, surgery, and watchful waiting [234]. This same dynamic could easily take hold in
the gene expression profiling arena with a proliferation of licensed gene expression
assays without any clear notion of what new ones are contributing over previous assays.
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Thus, future decision analyses of new gene expression profiling technologies in clinical
oncology should study their incremental clinical and economic value over pre-existing
gene expression profiling and clinicopathologic methods. For instance, our breast cancer
decision analytic model can be expanded to project the lifetime clinical and economic
consequences of early stage breast cancer under many different treatment strategies. Such
a model may begin with a decision to use the MammaPrint, the RS-assay, the RS-assay
following by the MammaPrint, Adjuvant!Online (AOL) following by the RS-assay, AOL
following by the MammaPrint or to continue with CCP.

6.2 Conclusion
The potential applications of certain gene expression profiling assays in clinical oncology
appear to be clinically promising and economically attractive in the Canadian healthcare
system. However, uncertainty about these gene expression profiling assays in real world
Canadian setting remains the primary challenge for adoption. Novel funding models such
as conditional funding alongside a field evaluation of these assays to establish their
impact on cancer management and patient survival may have a large societal impact and
should be initiated in Canada to ensure their clinical utility and cost-effectiveness.
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